

(18)



Europäisches Patentamt

European Patent Office

Office européen des brevets

(11) Publication number:

**0 126 449
B1**

(12)

EUROPEAN PATENT SPECIFICATION

(45) Date of publication of patent specification: 23.12.87

(51) Int. Cl.⁴: **C 07 D 295/14, A 61 K 31/495**(21) Application number: **84105643.5**(22) Date of filing: **17.05.84**(54) **Cardioselective aryloxy- and arylthio-hydroxypropyl piperazinyl acetanilides wich affect calcium entry.**(30) Priority: **18.05.83 US 495904**(43) Date of publication of application:
28.11.84 Bulletin 84/48(45) Publication of the grant of the patent:
23.12.87 Bulletin 87/52(84) Designated Contracting States:
AT BE CH DE FR GB IT LI LU NL SE(56) References cited:
**FR-A-2 267 104
US-A-3 652 568
US-A-3 654 277****CHEMICAL ABSTRACTS, vol. 90, no. 7,
February 12, 1979, Columbus, Ohio, USA, L.
STANKEVICIENE "Synthesis of N-(3-aryloxy-2-
hydroxy-propyl)-1-piperazines", page 601,
abstract no. 54 907c****The file contains technical information
submitted after the application was filed and
not included in this specification**(73) Proprietor: **SYNTEX (U.S.A.) INC.
3401 Hillview Avenue P.O. Box 10850
Palo Alto California 94303 (US)**(72) Inventor: **Kluge, Arthur Frederick
1683 Parkhills Avenue
Los Altos, Calif. 94020 (US)
Inventor: Clark, Robin Douglas
114 Lowell Avenue
Palo Alto, Calif. 94301 (US)
Inventor: Strosberg, Arthur Martin
120 Lucero Way
Portola Valley, Calif. 94025 (US)
Inventor: Pascal, Jean Claude
23-25 Allée des Hautes Bruyères
F-94230 Cachan (FR)
Inventor: Whiting, Roger Lewis
Research Park Heriot-Watt University
Currie Edinburgh Scotland (GB)**(74) Representative: **Barz, Peter, Dr. et al
Patentanwälte Dr. V. Schmied-Kowarzik Dipl.-
Ing. G. Dannenberg Dr. P. Weinhold Dr. D. Gudel
Dipl.-Ing. S. Schubert Dr. P. Barz
Siegfriedstrasse 8
D-8000 München 40 (DE)**

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European patent convention).

Courier Press, Leamington Spa, England.


EP 0 126 449 B1

Description

The present invention is concerned with compounds, compositions, and methods useful for treating diseases in human beings which are affected by calcium entry blockade. In particular, compounds wherein piperazine is bound through one nitrogen to an aryloxy or arylthio moiety by a hydroxypropylene or alkanoyloxypropylene linkage, and through the other nitrogen to an acetanilide residue are useful in this regard.


Large numbers of compounds are known which affect various physiological systems related to adrenergic control. Compounds which are related to the compounds of the present invention are disclosed in Belgian Patent No. 806,380 (U.S. Patent No. 3,944,549), and include 1-(1,4-benzodioxan-2-ylmethyl)-4-(2,6-dimethylphenylacetanilido)piperazine; in L. Stankeviciene, et al. in *Mater. Mezvug, Nauchv, Konf. Kaunos. Med. Inst.*, 25th (1976), published in 1977, pages 322-3 [*Chem. Abstr.*, 90 54907c (1979)]; and French Patent No. 2,267,104. Additional references of interest in this art include U.S. Patents Nos. 3,360,529; 3,496,183; 3,829,441; 3,879,401; 3,944,549; 4,059,621; 4,302,469; 4,315,939; 4,335,126; and 4,353,901. Calcium entry blocking compounds have been used to mediate the symptoms of cardiovascular diseases, such as, myocardial infarction, congestive heart failure, angina and arrhythmia. The present invention concerns a group of cardioselective compounds which are useful in the treatment of these cardiovascular diseases.

In one aspect this invention concerns piperazine derivatives of the general formula:



and the pharmaceutically acceptable esters and acid addition salts thereof, wherein:


R¹ and R⁵ are each C₁₋₄ alkyl;
R², R³ and R⁴ are each independently hydrogen, C₁₋₄ alkyl, C₁₋₄ alkoxy, cyano, trifluoromethyl, halo, C₁₋₄ alkylthio, C₁₋₄ alkyl sulfinyl or C₁₋₄ alkyl sulfonyl, an alkylamido group



wherein R¹⁶ is independently hydrogen or C₁₋₄ alkyl and R¹⁷ is C₁₋₄ alkyl, except that when R¹ is methyl, R⁴ is not methyl; or

R² and R³ together form —OCH₂O—;

R⁶, R⁷, R⁸, R⁹ and R¹⁰ are each independently hydrogen, an acyl group



wherein R¹⁵ is C₁₋₄ alkyl, aminocarbonylmethyl, phenyl, cyano, C₁₋₄ alkyl, C₁₋₄ alkoxy, trifluoromethyl, halo, C₁₋₄ alkylthio, C₁₋₄ alkyl sulfinyl or C₁₋₄ alkyl sulfonyl, di-C₁₋₄ alkyl amino; or

R⁶ and R⁷ together form —CH=CH—CH=CH—; or

R⁷ and R⁸ together form —OCH₂O—;

R¹¹ and R¹² are each independently hydrogen or C₁₋₄ alkyl; and

W is oxygen or sulfur.


These cardioselective compounds are useful in therapy in the treatment of cardiovascular diseases, including arrhythmias, variant and exercise induced angina and myocardial infarction.

Another aspect of this invention is a process for the preparation of compounds of formula I, as described in more detail hereinafter.

Definitions

As used herein:

"Aminocarbonylmethyl" refers to a group having the following structure



"Cyano" refers to a group having the following structure $\text{—C}\equiv\text{N}$.

"Di- C_{1-4} alkyl amino" refers to a group having the following structure $\text{R}^{13}(\text{R}^{14})\text{N—}$ wherein R^{13} and R^{14} are each independently C_{1-4} alkyl as defined herein.

"Halo" or "halogen" refers to fluoro, chloro, bromo or iodo usually regarding halo substitution for a hydrogen atom in an organic compound.

"Isomerism" refers to compounds having the same atomic mass and atomic number but differing in one or more physical or chemical properties. Various types of isomerism include the following:

"Stereoisomer" refers to a chemical compound having the same molecular weight, chemical composition, and constitution as another, but with the atoms grouped differently. That is, certain identical chemical moieties are at different orientations in space and, therefore, when pure, has the ability to rotate the plane of polarized light. However, some pure stereoisomers may have an optical rotation that is so slight that it is undetectable with present instrumentation.

"Optical isomerism" describes one type of stereoisomerism which manifests itself by the rotation that the isomer, either pure or in solution, imparts to the plane of polarized light. It is caused in many instances by the attachment of four different chemical atoms or groups to at least one of the carbon atoms in a molecule. These isomers may be described as D-, L-, or a D,L-pair or D-, L- or a D,L-pair; or R-, S-, or an R,S-pair, depending upon the nomenclature system employed.

"Diastereoisomer" refers to stereoisomers some or all of which are dissymmetric but which are not mirror images of each other. Diastereoisomers corresponding to a given structural formula must have at least two asymmetric atoms. A compound having two asymmetric atoms will usually exist in four diastereoisomeric forms, i.e. (–)-erythro, (+)-erythro, (–)-threo and (+)-threo.

Certain compounds of formula I wherein R^{12} is hydrogen will have one asymmetric carbon atom, i.e., the carbon atom 2 of the propyl moiety. These compounds will exist in two stereochemical forms; i.e. (+) and (–) or R and S- and mixtures thereof. Compounds of formula I where R^{12} is a group other than hydrogen will have two asymmetric carbon atoms, i.e. the carbon atom at the 2 position of the propyl moiety, and the carbon atom to which R^{12} is attached. These compounds may exist in four stereochemical forms (+)-erythro-, (–)-erythro-, (+)-threo-, (–)-threo and mixtures thereof. The Cahn-Prelog convention will describe these four isomers as R–R, R–S, S–R, and S–S, which denotes the stereochemistry at each of the asymmetric carbon atoms. The R and S designation will be used in this application. This patent application is to be interpreted to include the individual stereoisomers as well as mixtures thereof.

"Structure of formula I" refers to the generic structure of the compounds of the invention. The chemical bonds indicated as (E) in formula I indicate the nonspecific stereochemistry of the asymmetric carbon atoms, e.g. at position 2 of the propyl chain, i.e., the carbon to which is attached the hydroxyl (—OH) group, and the carbon to which R^{12} is attached between the piperazine ring and the carbonyl group.

"Acyl" includes such groups as acetyl, propanoyl and n-butanoyl.

" C_{1-4} alkyl" refers to a branched or unbranched saturated hydrocarbon chain of 1–4 carbons, such as, for example, methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl, s-butyl and t-butyl.

" C_{1-4} alkoxy" refers to a group —OR wherein R is C_{1-4} alkyl as herein defined.


" C_{1-4} alkylthio" refers to a group —SR wherein R is C_{1-4} alkyl as herein defined.

" C_{1-4} alkyl sulfinyl" refers to



wherein R is C_{1-4} alkyl as herein defined.

" C_{1-4} alkyl sulfonyl" refers to



wherein R is C_{1-4} alkyl as herein defined.


"Optional" or "optionally" means that the subsequently described event or circumstance may or may not occur, and that the description includes instances where said event or circumstance occurs and instances in which it does not. For example, "optionally substituted phenyl" means that the phenyl may or may not be substituted and that the description includes both unsubstituted phenyl and phenyl wherein there is substitution; "optionally followed by converting the free base to the acid addition salt" means that said conversion may or may not be carried out in order for the process described to fall within the invention, and the invention includes those processes wherein the free base is converted to the acid addition salt and those processes in which it is not.

"Pharmaceutically acceptable acid addition salt" refers to those salts which retain the biological effectiveness and properties of the free bases and which are not biologically or otherwise undesirable, formed with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid,


phosphoric acid and the like, and organic acids such as acetic acid, propionic acid, glycolic acid, pyruvic acid, oxalic acid, malic acid, malonic acid, succinic acid, maleic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, menthanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid and salicylic acid.

"Pharmaceutically acceptable ester" of the compound of formula I which may conveniently be used in therapy includes those containing the alkanoyloxy group, —O—C(=O)—Z , wherein Z is an alkyl group containing 1 to 12 carbon atoms, which is attached to carbon atom 2 of the propylene linkage instead of the hydroxyl group, i.e., the hydroxy group has been esterified. The group, Z, may be for example, methyl, ethyl, butyl, hexyl, octyl or dodecyl. This invention contemplates those compounds of formula I which are esters as described herein and at the same time are the pharmaceutically acceptable acid addition salts thereof.

"Piperazino" structure describes the following saturated six-membered dinitrogen substituted heterocyclic moiety:



The compounds of the present invention are generally named according to the IUPAC nomenclature system. The locants for the substituents on the ring system of the above compounds of the instant invention are as depicted in the Summary of the Invention above. For example, when R¹ and R⁵ are methyl, R⁶ is methoxy, R² to R⁴ and R⁷ to R¹² are hydrogen, and W is oxygen, the compound of formula I is named 1-[3-(2-methoxyphenoxy-2-hydroxypropyl)-4-[(2,6-dimethylphenyl)aminocarbonylmethyl]piperazine, and is shown below:




where * denotes a center or possible center of asymmetry. This compound may also be named as 1 - [3 - (2 - methoxyphenoxy) - 2 - hydroxypropyl] - 4 - (2,6 - dimethylphenylcarbamoylmethyl)piperazine; or 1 - [3 - (2 - methoxyphenoxy) - 2 - hydroxypropyl] - 4 - (2,6 - dimethylacetanilido)piperazine. For purposes of this patent application, the IUPAC designation first described above will be used.


The optically active compounds herein can be designated by a number of conventions; i.e., the R- and S-sequencing rules of Cahn and Prelog; erythro and threo isomers; D- and L-isomers; d- and l-isomers; and (+) and (-)-isomers, which indicates the direction a plane of polarized light is rotated by the chemical structure, either pure or in solution. These conventions are well-known in the art and are described in detail by E. L. Eliel in *Stereochemistry of Carbon Compounds*, published by McGraw Hill Book Company, Inc. of New York in 1962 and references cited therein.

In the Reaction Sequences as discussed herein:

"Ar¹" represents the aryl moiety which may optionally be substituted by R⁶ to R¹⁰ as defined hereinabove. The linkage to other parts of the molecule is through the carbon atom at the 1 position, i.e., to the oxygen or sulfur atom, and the other numbered positions of the aryl group are indicated, as shown:



"Ar²" represents an optionally substituted phenyl group wherein R¹ to R⁵ are as defined hereinabove, and the other numbered positions are shown.



Preferred embodiments of the present invention include those compounds of formula I wherein two substituents selected from R¹ to R⁵ are hydrogen and two substituents selected from R⁶ to R¹⁰ are hydrogen. A preferred subgroup are those compounds of formula I wherein W is oxygen; i.e., O.

A preferred subgroup are those compounds of formula I wherein the substituents R², R³ and R⁴ are hydrogen.

A presently preferred compound of the present invention includes those compounds of formula I wherein substituents R¹ and R⁵ are each methyl, R², R³, R⁴ and R⁶ to R¹² are each hydrogen and W is O; i.e., 1-[3-phenoxy-2-hydroxypropyl]-4-[(2,6-dimethylphenyl)aminocarbonylmethyl]piperazine.

A presently preferred compound of the present invention includes those compounds of formula I wherein R¹ and R⁵ are each methyl, R⁶ is methoxy, R², R³, R⁴ and R⁷ to R¹² are each hydrogen and W is O; i.e., 1-[3-(2-methoxyphenoxy)-2-hydroxypropyl]-4-[(2,6-dimethylphenyl)aminocarbonylmethyl]piperazine.

A presently preferred compound of the present invention includes those compounds of formula I wherein R¹ and R⁵ are each methyl, R⁶ is cyano, R², R³, R⁴ to R¹² are each hydrogen and W is O; i.e., 1-[3-(2-cyanophenoxy)-2-hydroxypropyl]-4-[(2,6-dimethylphenyl)aminocarbonylmethyl]piperazine.

Preferred embodiments include those compounds of formula I wherein the substituents R¹, R⁴ and R⁵ are hydrogen.

Preferred embodiments include those compounds of formula I wherein two non-hydrogen substituents R² and R³ are each halo, particularly chloro.

Preferred embodiments include those compounds of formula I wherein a maximum of one non-hydrogen substituent is selected from R¹ to R⁵. A presently preferred subgroup includes those compounds of formula I wherein one non-hydrogen substituent is R¹. A preferred subgroup includes those compounds of formula I wherein one substituent is C₁₋₄ alkoxy, particularly methoxy.

Embodiments of the present invention include those compounds of formula I wherein two non-hydrogen substituents are R⁷ to R⁹. A preferred subgroup are those compounds wherein R⁶ and R¹⁰ are C₁₋₄ alkoxy, particularly methoxy.

Preferred embodiments include those compounds of formula I wherein a maximum of one non-hydrogen substituent is selected from R⁶ to R¹⁰.

A preferred subgroup includes those compounds of formula I wherein one non-hydrogen substituent R⁶ is C₁₋₄ alkoxy, particularly methoxy.

A preferred subgroup includes those compounds of formula I wherein the substituent R⁶ is cyano or halo, particularly chloro.

A preferred subgroup of the present invention includes those compounds of formula I wherein the non-hydrogen substituent R⁶ is C₁₋₄ alkoxy, particularly methoxy, or chloro.

Embodiments of the present invention include those compounds of formula I wherein R¹¹ is hydrogen.

Embodiments of the present invention include those compounds of formula I wherein R¹² is hydrogen.

Embodiments of the present invention include those compounds of formula I wherein R¹¹ and R¹² are both hydrogen.

Embodiments of the present invention include those compounds of formula I wherein W is sulfur, i.e., S.

Presently preferred subgroups include those compounds wherein R¹² is C₁₋₄ alkyl, particularly methyl; and wherein R¹¹ and R¹² are each C₁₋₄ alkyl, particularly methyl.

Presently preferred compounds of the present invention are those wherein R⁶, R⁷, R⁸, R⁹ and R¹⁰ are each hydrogen.

Another presently preferred group of compounds are those wherein R¹¹ is hydrogen. Of this subgroup, those presently preferred are those compounds wherein all of R¹ to R¹⁰ are hydrogen. Preferred among these are compounds wherein R¹¹ is also hydrogen.

Especially preferred from those compounds wherein R¹¹ is hydrogen are the compounds selected from the group comprising:

1-[3-(2-methoxyphenoxy)-2-hydroxypropyl]-4-[(2,6-dimethylphenyl)aminocarbonylmethyl]piperazine;

and 1-[3-(1-naphthyl)-2-hydroxypropyl]-4-[(2,6-dimethylphenyl)aminocarbonylmethyl]piperazine.

An additional set of presently preferred compounds are those wherein R¹¹ and R¹² are methyl; presently preferred among these is:

1-[3-(2-methoxyphenoxy)-2-hydroxypropyl]-4-[(2,6-dimethylphenyl)-N-(methyl)aminocarbonyl-1-ethyl]piperazine.

A pharmaceutical composition useful for treating one or more cardiovascular diseases, such as arrhythmia, myocardial infarction and variant and exercise-induced angina, in a mammal, particularly a human being, which comprises a therapeutically effective amount of a compound of formula I or a pharmaceutically acceptable acid addition salt thereof in admixture with a pharmaceutically acceptable excipient.

A method for treating a cardiovascular disease, such as arrhythmia, myocardial infarction and variant and exercise-induced angina, in a mammal, particularly a human being, which method comprises administering to a subject in need of such treatment a therapeutically effective amount of the compound of formula I or a pharmaceutically acceptable acid addition salt thereof.

These embodiments also include the optical isomers (+) and (-) and R- and S- isomers and mixtures thereof. This invention includes the individual isomers and all possible mixtures thereof.


All of the aforementioned embodiments include the pharmaceutically acceptable esters and acid addition salts thereof, particularly the mono- and dihydrochlorides, and mixtures thereof.

Process for Preparation

Reaction Sequence(s) 1 and 2 shown below, are complementary processes for linking the two "halves" of the compounds of formula 1 through the piperazine ring.

In the Reaction Sequence(s) below, X represents a leaving group such as, for example, halo or sulfonyl ester group, preferably a halo group. The starting materials for these reaction sequence(s) are obtained as described below.

REACTION SEQUENCE 1



Reaction Sequence 1

The compound of formula A wherein Ar¹ is as described above is obtained by reacting the appropriate phenol and 2,3-isopropylidene-1-tosylpropane, hydrolysis with aqueous acid, then by reaction with methanesulfonyl chloride or toluenesulfonyl chloride and pyridine followed by reaction with sodium hydroxide, as is well known to those in the art ([see, for example, Caroon et al., *J. Med. Chem.* 24, 1320 (1981)]).

The intermediate aryloxy and arylthio epoxide compounds (formula A) are also prepared by reacting the unsubstituted or substituted phenol or thiophenol with epichlorohydrin in the presence of a strong

base, such as TRITON B, trialkyl amines, alkali metal hydroxides, alkoxides or hydrides, for example, sodium or potassium hydroxide, methoxide or hydride. The reaction is run in an inert solvent such as methanol, ethanol, dimethylformamide or dimethylsulfoxide at ambient temperature for about 20 hours, [See, for example, G. Shtacher, et al, *J. Med. Chem.*, Vol. 16, No. 5, p. 516ff (1973)].

The phenols and thiophenols are readily available or if not readily available may be prepared by methods well known in the art. For example, many of the substituted phenols are commercially available. These include the methyl-, dimethyl-, trimethyl-, ethyl-, diethyl-, propyl-, butyl-, methoxy-, dimethoxy-, trimethoxy-, ethoxy-, diethoxy-, propoxy-, butoxy-, cyano-, chloro-, dichloro-, trichloro-, tetrachloro-, pentachloro-, bromo-, dibromo-, tribromo-, fluoro-, difluoro-, trifluoro-, bromochloro-, bromofluoro-, chlorofluoro-, methylthio-, methylenedioxy- phenols and mixtures of the aforementioned compounds according to *Chemical Sources*, published by Directories Publishing Company, Inc., Flemington, New Jersey in 1979.

The methylsulfinyl and methylsulfonyl substituted phenols are prepared according to conventional procedures known in the art starting from the corresponding methylthiophenol, which is available from commercial sources or can be readily prepared. For instance, the o-methylsulfinylphenol is prepared by treating o-methylthiophenol with acetic anhydride to form the corresponding ester which is then treated with sodium periodate in methanol. Upon hydrolysis to remove the acetyl group using acidic or basic conditions, there is obtained o-methylsulfinylphenol. The o-methylsulfonyl phenol is obtained by treating the ester prepared above with hydrogen peroxide or 2-chloroperbenzoic acid in aqueous methanol. After hydrolysis to remove the acetyl group, there is obtained o-methylsulfonylphenol in good yield. The corresponding m- and p-substituted methylsulfinylphenols and methylsulfonylphenols are prepared by replacement of o-methylthiophenol by m-methyl- and p-methylthiophenol respectively.

These compounds of formula A can then be converted into the materials of formula E in Reaction Sequence 1 by reacting the resulting phenoxy substituted epoxide derivatives with piperazine (formula B), by heating in a solvent that will dissolve both reactants, using methods known to those in the art. (See Caroon et al., supra).

The compounds of formula F are prepared from the corresponding aniline, substituted aniline, or N-substituted aniline derivatives, of formula D which are commercially available, by reaction with α -haloacyl halides, such as monochloroacetyl chloride, or α -chloropropionyl chloride (compounds of formula C).

Many of the substituted anilines are commercially available. These include the methyl-, dimethyl-, trimethyl-, ethyl-, diethyl-, propyl-, butyl-, methoxy-, dimethoxy-, trimethoxy-, ethoxy-, diethoxy-, propoxy-, butoxy-, chloro-, dichloro-, trichloro-, tetrachloro-, pentachloro-, bromo-, dibromo-, tribromo-, fluoro-, difluoro-, trifluoro-, bromochloro-, bromofluoro-, chlorofluoro-, methylthio-, methylenedioxy- anilines and mixtures of the aforementioned compounds. Many N-alkylated aniline derivatives such as the N-methyl-, N-ethyl-, N-propyl- and N-butyl- anilines and substituted anilines are also commercially available according to *Chemical Sources*, published by Directories Publishing Company, Inc., Flemington, New Jersey in 1979.

The methylsulfinyl and methylsulfonyl substituted anilines are prepared according to conventional procedures known in the art starting from the corresponding methylthioaniline, which is available from commercial sources. For instance, the o-methylsulfinylaniline is prepared by treating o-methylthioaniline with acetic anhydride to form the corresponding acetanilide which is then treated with sodium periodate in methanol. Upon hydrolysis to remove the acetyl group using acidic or basic conditions, there is obtained o-methylsulfinylaniline. The o-methylsulfonyl aniline is obtained by treating the acetanilide prepared above with hydrogen peroxide or 2-chloroperbenzoic acid in aqueous methanol. After hydrolysis to remove the acetyl group, there is obtained o-methylsulfonylaniline in good yield. The corresponding m- and p-substituted methylsulfinylanilines and methylsulfonylanilines are prepared by replacement of o-methylthioaniline by m-methyl and p-methylthioaniline respectively.

The corresponding ethyl-, propyl-, and butyl-thioanilines are prepared by treatment of the commercially available aminothiophenol with sodium hydroxide followed by the appropriate alkyl iodide. The corresponding ethyl-, propyl-, and butyl-sulfinyl and sulfonylanilines are prepared by replacement of o-methylthioaniline with the appropriate alkylthioaniline in the procedures described above.

Many N-alkyl substituted anilines may be prepared by procedures known in the art, such as treatment of the unsubstituted or aryl-substituted anilines described herein using an alkyl halide such as methyl chloride, ethyl chloride, propyl chloride, butyl chloride or the like in a suitable solvent such as diethylether or methylene dichloride.

Many α -halo acid halides are commercially available, including for example, chloroacetyl chloride and 2-chloropropionyl chloride. 2-Chlorobutyric acid is commercially available and may be converted to the acid chloride by methods known in the art, such as reaction with thionyl chloride or phosphorus pentachloride. The α - or 2-chloroacid chlorides which are not readily available may be prepared by conventional methods such as the Hell-Volhard-Zelinsky Reaction in which the appropriate alkyl carboxylic acid is reacted with chlorine in the presence of phosphorus. See for example, *Organic Chemistry*, by R. T. Morrison and R. N. Boyd, 2nd Edition, Ch. 18, p 604, and *Chem. Revs.*, Vol. 7, p 180 (1930).

To carry out this reaction to produce compounds of formula F, the aniline derivative, a basic amine, such as triethylamine or pyridine, preferably triethylamine, and the chloroacyl chloride are dissolved in an inert aprotic organic solvent, such as, for example, benzene, chloroform, carbon tetrachloride, methylene or methylene chloride, preferably methylene chloride. The aniline and tertiary amine are in approximately

Compounds of formula I wherein Ar¹, Ar², R¹ to R¹² and W are as defined above are prepared by reacting compounds of formula E with compounds of the formula F in the presence of a solvent such as toluene/methanol mixture, ethanol and dimethylformamide. The reaction mixture is heated to a temperature of about 60°C to about 150°C, preferably to about 70°C to about 90°C for about 6 hours to about 24 hours.

Isolation and purification of the compounds and intermediates described can be effected, if desired, by any suitable separation or purification procedure such as, for example, filtration, extraction, crystallization, column chromatography, thin-layer chromatography or thick-layer chromatography, or a combination of these procedures. Specific illustrations of suitable separation and isolation procedures can be had by reference to the examples hereinbelow. However, other equivalent separation or isolation procedures could, of course, also be used.

The salt products are also isolated by conventional means. For example, the reaction mixtures may be evaporated to dryness, and the salts can be further purified by conventional methods.

The compounds of formula I produced by any of the Reaction Sequences described herein may exist as R- or S-isomers (or erythro and threo isomers). Accordingly, the compounds of the present invention may be prepared in either the R- or S- forms or as mixtures thereof. Unless specified, the compounds of the instant invention are a mixture of R- and S- forms. However, the scope of the subject invention is not considered to be limited to the R/S- mixture but encompasses the individual isomers of the subject compounds as well.

If desired, a mixture of the intermediates used to prepare compounds of formula I or the final product may be separated by, e.g., recrystallization and chromatography. It is preferred to prepare the individual isomers from the isomeric intermediates of the compound of formula I.

Alternatively, the compounds of formula I may be prepared according to Reaction Sequence 2 wherein Ar¹, Ar², R¹ to R¹² and W are as described above.

Compound (B) + Compound (F)

↓

Ar¹-W-CH₂-CH-CH₂ + HN(CH₂)₆N-CH(R¹²)-C(=O)-N(R¹¹)-Ar²

(A) (G)

↓

Ar¹-W-CH₂-CH(OH)-CH₂-N(CH₂)₆N-CH(R¹²)-C(=O)-N(R¹¹)-Ar²

(I)

The compounds of formula F are produced by the reaction of a compound of formula C and a compound of formula D as was described above in Reaction Sequence 1.

The compounds of formula G are prepared from the corresponding compounds of formula F by reaction with piperazine (formula B), by means well known to those in the art, similar to those utilized in converting the compounds of formula E and F into compounds of formula I. In this procedure, in both cases, the halide is mixed with an excess of piperazine or a substituted piperazine, specifically about a 3 to 5 molar excess, preferably about a 4 molar excess in a polar organic solvent, such as ethanol or propanol, preferably ethanol or ethanol/water (50/50), and the mixture is heated to 50° to 100°, preferably the reflux temperature of the solvent for 1 to 4 hours, preferably about 2 hours. The product of formula G may be isolated by conventional means.

The compounds of formula I are then prepared and isolated in a manner similar to that described above for the reaction of compounds of formulas A and B in Reaction Sequence 1 by combining the compounds of formulas A and G.

5 The coupling step, usually the final step, of the processes of Reaction Sequences 1 and 2, is carried out in substantially similar fashion to each other. The compounds of formulas E and F or alternatively the compounds of formula A and G are combined in essentially equimolar amounts in an aprotic organic polar solvent, such as, for example, dimethylformamide or tetrahydrofuran, preferably dimethylformamide. The reaction mixture is heated to about 50° to about 100°, preferably about 60 to about 70° and then the temperature raised to about 70 to 110°, preferably 85 to 95° and allowed to react for about 1 to about 24 hours, preferably overnight. The condensed product of formula I is then isolated by conventional means.

10 The compounds of formula I described herein may exist as mixtures of optical isomers because of the possible two asymmetric carbon atoms. Accordingly, the compounds of the present invention may be prepared in either optically active form or as racemic mixtures. Unless otherwise specified, the compounds described herein are all in the racemic form. However, the scope of the subject invention herein is not considered to be limited to a mixture of the racemic forms but to encompass all of the individual optical isomers as well.

If desired, racemic intermediates of compounds of formula A, A', C, E, F or G (supra) or final product, i.e., formula I prepared herein may be resolved into their optical antipodes by conventional resolution means known in the art, for example, by the separation (e.g., fractional crystallization) of the diastereomeric salts formed by reaction of, e.g., racemic compounds of formula I or the intermediate compounds of formula A, A', C, E, F or G (supra) with an optically active acid. Exemplary of such optically active acids are the optically active forms of camphor-10-sulfonic acid, α -bromocamphor-n-sulfonic acid, camphoric acid, menthoxyacetic acid, tartaric acid, malic acid, diacetyltartaric acid and pyrrolidone-5-carboxylic acids, and, where necessary, bases such as cinchonidine and brucine. The separated pure diastereomeric salts may then be cleaved by standard means to afford the respective optical isomers of the compounds of formula I or the intermediates of formula A, A', C, F, F or G (supra).

20 The compounds of formula I may be isolated as free bases, but it is usually more convenient to isolate the compounds of the instant invention as acid addition salts. These salts are prepared in the usual manner, i.e., by reaction of the free base with a suitable organic or inorganic acid, for example, one of the pharmaceutically acceptable acids described above. The base of formula I, dissolved in an unreactive solvent such as an alcohol, e.g., methanol and ethanol, or an ether, e.g., diethyl ether, is acidified with an acid dissolved in a like solvent. The acid solution is added until precipitation of the salt is complete. The reaction is carried out at a temperature of 20° to 50°C, preferably at room temperature. If desired, the salt can be readily converted to the free base by treatment with a base such as potassium or sodium carbonate or ammonium, potassium, or sodium hydroxide.

30 The compounds of formula I in free base form may be converted to the acid addition salts by treating with the appropriate organic or inorganic acid, such as, phosphoric, pyruvic, hydrochloric or sulfuric acid. Typically, the free base is dissolved in a polar organic solvent such as ethanol or methanol, and the acid added thereto. The temperature is maintained between about 0°C and about 100°C. The resulting acid addition salt precipitates spontaneously or may be brought out of solution with a less polar solvent.

40 The acid addition salts of the compounds of formula I may be decomposed to the corresponding free base by treating with a suitable base, such as potassium carbonate or sodium hydroxide, typically in the presence of aqueous solvent, and at a temperature of between about 0°C and 100°C. The free base form is isolated by conventional means, such as extraction with an organic solvent.

45 The pharmaceutically acceptable esters of the compound of formula I and the pharmaceutically acceptable acid addition salts of the esters thereof are prepared by treatment with an excess, about 1.1 to about 2 equivalents of the corresponding acid anhydride or acyl halide in the presence of a catalyst such as pyridine under conditions of about -10° to about +10°C for about 0.5 to about 12 hours, conditions which are known in the art and described in the Example below. (See for example, the appropriate sections of Morrison and Boyd, *supra* and Fieser and Fieser, *Reagents for Organic Synthesis*, Jon Wiley and Sons, Inc., New York, published in 1967). Suitable esters which are prepared include acetates, propionates, butanoates, hexanoates, octanoates and dodecanoates. The pharmaceutically acceptable acid addition salts of the esters of the compound of formula I are then prepared as described in Examples 6, 8 or 9 below.

50 Salts of the compounds of formula I may be interchanged by taking advantage of differential solubilities and volatilities, or by treating with the appropriately loaded ion exchange resin. This conversion is carried out at a temperature between about 0°C and the boiling point of the solvent being used as the medium for the procedure.

In summary then, the compounds of formula I are prepared by:

60 reacting an unsubstituted or substituted aryloxy- or arylthio-2-hydroxypropylpiperazine (formula E) [which according to one alternative can be formed by the coupling of a 1-aryloxy- or 1-arylthio-2,3-epoxypropane (formula A) with piperazine (formula B) to form the N-substituted piperazine (formula E)]; and

65 the substituted halo alkylanilide (formula F) [which according to one alternative can be formed by the coupling of 2-haloalkylcarboxyl halide (formula C) with the unsubstituted or substituted aniline (formula D)].

Alternatively, the compounds of formula I are prepared by:

reacting an unsubstituted or substituted 1-(aryloxy) or 1-(arylthio)-2,3-epoxypropane (formula A); and the N-substituted piperazine (formula G) [which according to one alternative can be formed by the coupling of 2-haloalkylcarboxylhalide (formula C) with the unsubstituted or substituted aniline (formula D) to produce compound of formula F which is coupled with piperazine (formula B)].

Alternatively, the compound of formula I is prepared by converting a salt of formula I to a free base by using a stoichiometric excess of a base.

Alternatively, the free base of the compound of formula I is converted to a pharmaceutically acceptable acid addition salt by use of a stoichiometric excess of an acceptable acid.

Alternatively, the salt of the compound of formula I is converted to a different salt of the compound of formula I by use of a stoichiometric excess of an acceptable different acid.

One process by which the compounds of the invention may be prepared comprises reacting a first reactant being piperazine bearing one of the said chain arms of the compound of formula (I), with a second reactant being a source of the other side chain arm of the compound of formula (I). Suitably the first reactant may be a compound of formula (E) or (G) as hereinbefore defined, and suitably the second reactant may be the corresponding compound of formula (F) or (A) as hereinbefore defined.

Utility and Administration

The compounds of the invention have been shown to effect calcium entry and β -blockade in experimental animal preparations, using *in vitro* preparations and animal tissue cultures. See for example, Kent et al., *Federation Proceedings*, Vol. 40, p. 724 (1981), Killam, et al., *Federation Proceedings*, Vol. 42, p. 1244 (1983) and Cotten et al., *Journal Pharm. Exp. Therap.*, Vol. 121, pp. 183—190 (1957). The compounds have been shown to be effective in animal models for cardiovascular diseases such as arrhythmia, angina, and myocardial infarction. These compounds are, therefore, useful in a treating cardiovascular disease, particularly myocardial infarction, variant and exercise-induced angina and arrhythmias, in a mammal, particularly a human being.

Administration of the active compounds and salts described herein can be via any of the accepted modes of administration for therapeutic agents. These methods include oral, parenteral, transdermal, subcutaneous and other systemic modes. The preferred method of administration is oral, except in those cases where the subject is unable to ingest, by himself, any medication. In those instances it may be necessary to administer the composition parenterally.

Depending on the intended mode, the compositions may be in the form of solid, semi-solid or liquid dosage forms, such as, tablets, suppositories, pills, capsules, powders, liquids and suspensions, preferably in unit dosage forms suitable for single administration of precise dosages. The compositions will include a conventional pharmaceutical excipient and an active compound of formula I or the pharmaceutically acceptable salts thereof and, in addition, may include other medicinal agents, pharmaceutical agents, carriers, adjuvants, diluents, etc.

The amount of active compound administered will, of course, be dependent on the subject being treated, the subject's weight, the severity of the affliction, the manner of administration and the judgment of the prescribing physician. However, an effective dosage is in the range of 0.1—10 mg/kg/day, preferably 0.5—5 mg/kg/day. For an average 70 kg human this would amount to 7—700 mg per day, or preferably 35—350 mg/day.

Since all of the effects of the compounds herein (antiinfarction, variant and exercise induced angina inhibition and antiarrhythmia) are achieved through a similar mechanism (effecting calcium entry blockade) dosages (and forms of administration) are within the same general and preferred ranges for all these utilities.

For solid compositions, conventional non-toxic solid include, for example, pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharin, talcum, cellulose, glucose, sucrose, magnesium carbonate may be used. The active compound as defined above may be formulated as suppositories using, for example, polyalkylene glycols, for example, propylene glycol, as the carrier. Liquid pharmaceutically administerable compositions can, for example, be prepared by dissolving, dispersing, etc. an active compound as defined above and optional pharmaceutical adjuvants in a excipient, such as, for example, water, saline, aqueous dextrose, glycerol or ethanol, to form a solution or suspension. If desired, the pharmaceutical composition to be administered may also contain minor amounts of nontoxic auxiliary substances such as wetting or emulsifying agents, pH buffering agents and the like, for example, sodium acetate, sorbitan monolaurate, triethylanolamine sodium acetate, triethanolamine oleate, etc. Actual methods of preparing such dosage forms are known, or will be apparent, to those skilled in this art; for example, see *Remington's Pharmaceutical Sciences*, Mack Publishing Company, Easton, Pennsylvania, 15th Edition, 1975. The composition or formulation to be administered will, in any event, contain a quantity of the active compound(s), a therapeutically effective amount, i.e. in an amount effective to alleviate the symptoms of the subject being treated.

For oral administration, a pharmaceutically acceptable non-toxic composition is formed by the incorporation of any of the normally employed excipients, such as pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharin, talcum, cellulose, glucose, sucrose and magnesium carbonate. Such compositions take the form of solutions, suspensions, tablets, pills, capsules,

powders, sustained release formulations and the like. Such compositions may contain 10%—95% active ingredient, preferably 1—70%.

Parenteral administration is generally characterized by injection, either subcutaneously, intramuscularly or intravenously. Injectables can be prepared in conventional forms, either as liquid solutions or suspensions, solid forms suitable for solution or suspension in liquid prior to injection, or as emulsions. Suitable excipients are, for example, water, saline, dextrose, glycerol and ethanol. In addition, if desired, the pharmaceutical compositions to be administered may also contain minor amounts of non-toxic auxiliary substances such as wetting or emulsifying agents and pH buffering agents, such as sodium acetate, sorbitan monolaurate and triethanolamine oleate.

A more recently devised approach for parenteral administration employs the implantation of a slow-release or sustained-release system, such that a constant level of dosage is maintained. See, e.g., U.S. Patent No. 3,710,795, which is incorporated herein by reference.

The following preparations and examples serve to illustrate the invention. They should not be construed as narrowing it, or limiting its scope.

Preparation A

(Preparation of Compounds of formula A)

(a) To 2-methoxyphenol (76 g) dissolved in about 60 ml of water and 200 ml of dioxane containing 29 g of sodium hydroxide is slowly added a large excess of epichlorohydrin (80 g). The solution is stirred at reflux temperature for 3 hrs. The mixture is diluted with ether, washed with two portions of water and dried using anhydrous magnesium sulfate. Evaporation of the dried extract, followed by distillation of the residue produced the product, 1-(2-methoxyphenoxy)-2,3-epoxypropane.

(b) Similarly, proceeding as in Subpart (a) above, but substituting a stoichiometrically equivalent of:

- 2-methylphenol;
- 3-methylphenol;
- 4-methylphenol;
- 4-n-butylphenol;
- 2-methoxyphenol;
- 4-methoxyphenol;
- 2-isopropoxyphenol;
- 2-n-butoxyphenol;
- 2-chlorophenol;
- 4-chlorophenol;
- 4-bromophenol;
- 2,4-dimethylphenol;
- 2,4-dichlorophenol;
- 4-methyl-5-chlorophenol;
- 3,4,5-trichlorophenol;
- 3,4,5-trimethoxyphenol;
- 3-methyl-4,5-dichlorophenol;
- 3-methyl-4-chloro-5-methoxyphenol;
- 2,3,4,5-tetrabromophenol;
- 3,6-dimethyl-4,5-dichlorophenol;
- 4-trifluoromethylphenol;
- 4-methylthiophenyl;
- 4-n-butylthiophenol;
- 4-methylsulfinylphenol;
- 4-n-butylsulfinylphenol;
- 4-methylsulfonylphenol;
- 4-n-butylsulfonylphenol;
- 2-cyanophenol;
- 2-acetylphenol;
- 4-n-butanoylphenol;
- 4-(N,N-dimethylamino)phenol;
- 4-(N,N-di-n-butylamino)phenol;
- 1-naphthol; thiophenol; or
- 4-methylphenylthiol

for 2-methoxyphenol, the following epoxide compounds of formula A are obtained:

- 1-(2-methylphenoxy)-2,3-epoxypropane;
- 1-(3-methylphenoxy)-2,3-epoxypropane;
- 1-(4-methylphenoxy)-2,3-epoxypropane;
- 1-(4-n-butylphenoxy)-2,3-epoxypropane;
- 1-(2-methoxyphenoxy)-2,3-epoxypropane;
- 1-(4-methoxyphenoxy)-2,3-epoxypropane;
- 1-(2-isopropoxyphenoxy)-2,3-epoxypropane;

- 1-(2-n-butoxyphenoxy)-2,3-epoxypropane;
 1-(2-chlorophenoxy)-2,3-epoxypropane;
 1-(4-chlorophenoxy)-2,3-epoxypropane;
 1-(4-bromophenoxy)-2,3-epoxypropane;
 5 1-(2,4-dimethylphenoxy)-2,3-epoxypropane;
 1-(2,4-dichlorophenoxy)-2,3-epoxypropane;
 1-(4-methyl-5-chlorophenoxy)-2,3-epoxypropane;
 1-(3,4,5-trichlorophenoxy)-2,3-epoxypropane;
 1-(3,4,5-trimethoxyphenoxy)-2,3-epoxypropane;
 10 1-(3-methyl-4,5-dichlorophenoxy)-2,3-epoxypropane;
 1-(3-methyl-4-chloro-5-methoxyphenoxy)-2,3-epoxypropane;
 1-(2,3,4,5-tetrabromophenoxy)-2,3-epoxypropane;
 1-(3,6-dimethyl-4,5-dichlorophenoxy)-2,3-epoxypropane;
 1-(4-trifluoromethylphenoxy)-2,3-epoxypropane;
 15 1-(4-methylthiophenoxy)-2,3-epoxypropane;
 1-(4-n-butylthiophenoxy)-2,3-epoxypropane;
 1-(4-methylsulfinylphenoxy)-2,3-epoxypropane;
 1-(4-n-butylsulfinylphenoxy)-2,3-epoxypropane;
 1-(4-methylsulfonylphenoxy)-2,3-epoxypropane;
 20 1-(4-n-butylsulfonylphenoxy)-2,3-epoxypropane;
 1-(2-cyanophenoxy)-2,3-epoxypropane;
 1-(2-acetylphenoxy)-2,3-epoxypropane;
 1-[(4-n-butanoylphenoxy)-2,3-epoxypropane];
 1-[4-(N,N-dimethylamino)phenoxy]-2,3-epoxypropane;
 25 1-[4-(N,N-di-n-butylamino)phenoxy]-2,3-epoxypropane;
 1-(1-naphthoxy)-2,3-epoxypropane;
 1-(phenylthio)-2,3-epoxypropane; or
 1-(4-methylphenylthio)-2,3-epoxypropane.

These compounds are of sufficient purity for use in Reaction Sequences 1 and 2.

- 30 (c) Similarly, proceeding as in Subpart (a) of this Preparation but substituting a stoichiometrically equivalent amount of 5-epichlorohydrin for epichlorohydrin, there is obtained the R-1-(2-methoxyphenoxy)-2,3-epoxypropane in good yield.

- (d) Similarly, proceeding as in Subpart (c) of this Preparation but substituting a stoichiometrically equivalent amount of the substituted phenol cited for 2-methoxyphenol, the corresponding R-substituted phenoxy epoxide compounds of formula A are obtained.

- 35 (e) Similarly, proceeding in Subpart (a) of this Preparation but substituting a stoichiometrically equivalent amount of R-epichlorohydrin for epichlorohydrin, there is obtained the corresponding (S)-1-(2-methoxyphenoxy)-2,3-epoxypropane in good yield.

- (f) Similarly, proceeding in Subpart (e) of this Preparation but substituting a stoichiometrically equivalent amount of R-epichlorohydrin for epichlorohydrin and a substituted phenol for 2-methoxyphenol, there is obtained a corresponding (S)-1-substituted-phenoxy-2,3-epoxypropane in good yield.

- (g) Similarly proceeding in Subparts (a), (b), (c), (d), (e) or (f) above but substituting a stoichiometrically amount of an optionally substituted phenylthiol derivative for 2-methoxyphenol, there is obtained 45 corresponding the R-, S- or R,S- 1-(optionally substituted-phenylthio)-2,3-epoxypropane.

Preparation B

Preparation of [(2,6-dimethylphenyl)aminocarbonylmethyl]chloride (Compound of formula F)

- 50 (a) 2,6-Dimethylaniline (96 g, 793 mmoles) and triethylamine (TEA) (96 g, 130 ml) are dissolved in one liter of methylene chloride. The mixture is cooled in ice, and the chloroacetyl chloride (89.6 g, 800 mmoles) is added slowly. The mixture is stirred for 4 hours and becomes very dark in color. The mixture is then washed with dilute hydrochloric acid, and concentrated under vacuum. Hexane is added to precipitate the product, [(2,6-dimethylphenyl)aminocarbonylmethyl]chloride, and the crude product is filtered, is washed and dried. A yield of 130 g is obtained, in sufficient purity for use in Reaction Sequences 1 or 2.

- 55 (b) Repeating the above procedure in a similar manner and substituting a stoichiometrically equivalent of:

2,3,4,6-tetramethylaniline;
 3-chloro-2,4,6-trimethylaniline;
 N-methyl-2,6-dimethylaniline; or

- 60 N-n-butyl-2,6-dimethylaniline for 2,6-dimethylaniline, there are obtained the following substituted chlorides of formula F:

[(2,3,4,6-tetramethylphenyl)aminocarbonylmethyl]chloride;
 [(3-chloro-2,4,6-trimethylphenyl)aminocarbonylmethyl]chloride;
 [N-methyl-N-(2,6-dimethylphenyl)aminocarbonylmethyl]chloride; or
 65 [N-n-butyl-N-(2,6-dimethylphenyl)aminocarbonylmethyl]chloride

of sufficient purity for use in Reaction Sequences 1 or 2.

(c) Repeating the above procedure in Subpart (a) in a similar manner and substituting a stoichiometrically equivalent amount of:

- 2-chloropropanoyl chloride;
- 2-chloro-n-butanoyl chloride; or
- 2-chloro-n-hexanoyl chloride

for chloroacetylchloride, there is obtained the following substituted chloride of formula F:

- [(2,6-dimethylphenyl)aminocarbonyl-1-ethyl]chloride;
- [(2,6-dimethylphenyl)aminocarbonyl-1-n-propyl]chloride; or
- [(2,6-dimethylphenyl)aminocarbonyl-1-n-pentyl]chloride.

(d) Repeating the above procedure in Subpart (a) in a similar manner and substituting a stoichiometrically equivalent amount of

- N-methyl-2,6-dimethylaniline; or
- N-n-butyl-2,6-dimethylaniline

for 2,6-dimethylaniline and 2-chloropropanoyl chloride for chloroacetylchloride, there is obtained the corresponding

- [N-methyl-N-(2,6-dimethylphenyl)aminocarbonyl-1-ethyl]chloride; or
- [N-n-butyl-N-(2,6-dimethylphenyl)aminocarbonyl-1-ethyl]chloride.

(e) Repeating the above procedure in Subpart (a) in a similar manner and substituting a stoichiometrically equivalent amount of

- N-methyl-2,6-dimethylaniline; or
- N-n-butyl-2,6-dimethylaniline

for 2,6-dimethylaniline, and 2-chloro-n-hexanoyl chloride for chloroacetyl chloride, there is obtained the corresponding

- [N-methyl-N-(2,6-dimethylphenyl)aminocarbonyl-1-n-pentyl]chloride; or
- [N-n-butyl-N-(2,6-dimethylphenyl)aminocarbonyl-1-n-pentyl]chloride.

Preparation C

Preparation of 1-[(2,6-dimethylphenyl)aminocarbonylmethyl]piperazine (Compound of formula G)

(a) The crude [(2,6-dimethylphenyl)aminocarbonylmethyl]chloride, prepared in Preparation B (50 g, 0.25 mole) and piperazine (86 g, 1 mole) are dissolved in 500 ml of ethanol. The mixture is refluxed for two hours, and then cooled and evaporated. The product is harvested by adding aqueous ammonia to the residue, and extracting with methylene chloride. Three portions of methylene chloride are used, which are collected, washed with water, and evaporated to a semi-solid. Upon addition of ether, the product crystallizes and is filtered. The resulting crude mixture is boiled with ether and then evaporated to a residue and triturated with hexane to yield pure material, 1-[(2,6-dimethylphenyl)aminocarbonylmethyl]piperazine. This material is of sufficient purity for use in Reaction Sequences 1 or 2.

(b) Repeating the above procedure [Subpart (a)] in a similar manner and substituting a stoichiometrically equivalent of:

- [(2,4,6-trimethylphenyl)aminocarbonylmethyl]chloride;
- [N-methyl-N-(2,6-dimethylphenyl)aminocarbonylmethyl]chloride;
- [N-n-butyl-N-(2,6-dimethylphenyl)aminocarbonylmethyl]chloride;
- [(2,6-dimethylphenyl)aminocarbonyl-1-ethyl]chloride;
- [N-methyl-N-(2,6-dimethylphenyl)aminocarbonyl-1-ethyl]chloride;
- [N-methyl-N-(2,6-dimethylphenyl)aminocarbonyl-1-ethyl]chloride;
- [N-n-butyl-N-(2,6-dimethylphenyl)aminocarbonyl-1-ethyl]chloride;
- [(2,6-dimethylphenyl)aminocarbonyl-1-n-pentyl]chloride;
- [N-methyl-N-(2,6-dimethylphenyl)aminocarbonyl-1-n-pentyl]chloride; or
- [N-n-butyl-N-(2,6-dimethylphenyl)aminocarbonyl-1-n-pentyl]chloride

for [(2,6-dimethylphenyl)aminocarbonylmethyl]chloride, there are obtained the following piperazines:

- 1-[(2,4,6-trimethylphenyl)aminocarbonylmethyl]piperazine;
- 1-[N-methyl-N-(2,6-dimethylphenyl)aminocarbonylmethyl]piperazine;
- 1-[N-n-butyl-N-(2,6-dimethylphenyl)aminocarbonylmethyl]piperazine;
- [(2,6-dimethylphenyl)aminocarbonyl-1-ethyl]piperazine;
- [N-methyl-N-(2,6-dimethylphenyl)aminocarbonyl-1-ethyl]piperazine;
- [N-methyl-N-(2,6-dimethylphenyl)aminocarbonyl-1-ethyl]piperazine;
- [N-n-butyl-N-(2,6-dimethylphenyl)aminocarbonyl-1-ethyl]piperazine;
- [(2,6-dimethylphenyl)aminocarbonyl-1-n-pentyl]piperazine;
- [N-methyl-N-(2,6-dimethylphenyl)aminocarbonyl-1-n-pentyl]piperazine; or
- [N-n-butyl-N-(2,6-dimethylphenyl)aminocarbonyl-1-n-pentyl]piperazine in sufficient purity for use in

Reaction Sequences 1 and 2.

Preparation D

Preparation of 1-[3-(2-methoxyphenoxy)-2-hydroxypropyl]piperazine (Compound of formula E)

(a) In a manner similar to that described in Subpart (a) of Preparation C, but substituting 1-(2-

methoxyphenoxy)-2,3-epoxypropane for the starting chloride and maintaining at ambient temperature for two days, one obtains the corresponding compound of formula E, namely

1-[3-(2-methoxyphenoxy)-2-hydroxypropyl]piperazine.

(b) Repeating the above procedure [Subpart (a)] in a similar manner and substituting a stoichiometrically equivalent amount of:

- 1-(2-methylphenoxy)-2,3-epoxypropane;
 - 1-(2-methoxyphenoxy)-2,3-epoxypropane;
 - 1-(2-chlorophenoxy)-2,3-epoxypropane;
 - 1-(2-bromophenoxy)-2,3-epoxypropane;
 - 1-(4-methylphenoxy)-2,3-epoxypropane;
 - 1-(4-methoxyphenoxy)-2,3-epoxypropane;
 - 1-(2-isopropoxyphenoxy)-2,3-epoxypropane;
 - 1-(2-n-butoxyphenoxy)-2,3-epoxypropane;
 - 1-(4-chlorophenoxy)-2,3-epoxypropane;
 - 1-(2,4-dimethylphenoxy)-2,3-epoxypropane;
 - 1-(2,4-dichlorophenoxy)-2,3-epoxypropane;
 - 1-(3,4,5-trichlorophenoxy)-2,3-epoxypropane;
 - 1-(3,4,5-trimethoxyphenoxy)-2,3-epoxypropane;
 - 1-(3-methyl-4-chloro-5-methoxyphenoxy)-2,3-epoxypropane;
 - 1-(2,3,4,5-tetrabromophenoxy)-2,3-epoxypropane;
 - 1-(2,6-dimethyl-3,4-dichlorophenoxy)-2,3-epoxypropane;
 - 1-(4-trifluoromethylphenoxy)-2,3-epoxypropane;
 - 1-(4-methylthiophenoxy)-2,3-epoxypropane;
 - 1-(4-methylsulfinylphenoxy)-2,3-epoxypropane;
 - 1-(4-methylsulfonylphenoxy)-2,3-epoxypropane;
 - 1-(4-n-butylthiophenoxy)-2,3-epoxypropane;
 - 1-(4-n-butylsulfinylphenoxy)-2,3-epoxypropane;
 - 1-(4-n-butylsulfonylphenoxy)-2,3-epoxypropane;
 - 1-(2-acetylphenoxy)-2,3-epoxypropane;
 - 1-(4-n-butanoylphenoxy)-2,3-epoxypropane;
 - 1-(4-aminocarbonylmethylphenoxy)-2,3-epoxypropane;
 - 1-(4-N,N-dimethylaminophenoxy)-2,3-epoxypropane;
 - 1-(4-N,N-di-n-butylaminophenoxy)-2,3-epoxypropane;
 - 1-(1-naphthoxy)-2,3-epoxypropane;
 - 1-(phenylthio)-2,3-epoxypropane; or
 - 1-(4-methylphenylthio)-2,3-epoxypropane for 1-[(2,6-dimethylphenyl)aminocarbonylmethyl]chloride,
- there are obtained the following piperazines:
- 1-[3-(2-methylphenoxy)-2-hydroxypropyl]piperazine;
 - 1-[3-(2-methoxyphenoxy)-2-hydroxypropyl]piperazine;
 - 1-[3-(2-chlorophenoxy)-2-hydroxypropyl]piperazine;
 - 1-[3-(2-bromophenoxy)-2-hydroxypropyl]piperazine;
 - 1-[3-(4-methylphenoxy)-2-hydroxypropyl]piperazine;
 - 1-[3-(4-methoxyphenoxy)-2-hydroxypropyl]piperazine;
 - 1-[3-(2-isopropoxyphenoxy)-2-hydroxypropyl]piperazine;
 - 1-[3-(2-n-butoxyphenoxy)-2-hydroxypropyl]piperazine;
 - 1-[3-(4-chlorophenoxy)-2-hydroxypropyl]piperazine;
 - 1-[3-(2,4-dimethylphenoxy)-2-hydroxypropyl]piperazine;
 - 1-[3-(2,4-dichlorophenoxy)-2-hydroxypropyl]piperazine;
 - 1-[3-(3,4,5-trichlorophenoxy)-2-hydroxypropyl]piperazine;
 - 1-[3-(3,4,5-trimethoxyphenoxy)-2-hydroxypropyl]piperazine;
 - 1-[3-(3-methyl-4-chloro-5-methoxyphenoxy)-2-hydroxypropyl]piperazine;
 - 1-[3-(2,3,4,5-tetrabromophenoxy)-2-hydroxypropyl]piperazine;
 - 1-[3-(2,6-dimethyl-3,4-dichlorophenoxy)-2-hydroxypropyl]piperazine;
 - 1-[3-(4-trifluoromethylphenoxy)-2-hydroxypropyl]piperazine;
 - 1-[3-(4-methylthiophenoxy)-2-hydroxypropyl]piperazine;
 - 1-[3-(4-methylsulfinylphenoxy)-2-hydroxypropyl]piperazine;
 - 1-[3-(4-methylsulfonylphenoxy)-2-hydroxypropyl]piperazine;
 - 1-[3-(4-n-butylthiophenoxy)-2-hydroxypropyl]piperazine;
 - 1-[3-(4-n-butylsulfinylphenoxy)-2-hydroxypropyl]piperazine;
 - 1-[3-(4-n-butylsulfonylphenoxy)-2-hydroxypropyl]piperazine;
 - 1-[3-(2-acetylphenoxy)-2-hydroxypropyl]piperazine;
 - 1-[3-(4-n-butanoylphenoxy)-2-hydroxypropyl]piperazine;
 - 1-[3-(4-aminocarbonylmethylphenoxy)-2-hydroxypropyl]piperazine;
 - 1-[3-(4-N,N-dimethylaminophenoxy)-2-hydroxypropyl]piperazine;
 - 1-[3-(4-N,N-di-n-butylaminophenoxy)-2-hydroxypropyl]piperazine;

1-[3-(1-naphthoxy)-2-hydroxypropyl]piperazine;
 1-[3-(phenylthio)-2-hydroxypropyl]piperazine; or
 1-[3-(4-methylphenylthio)-2-hydroxypropyl]piperazine.

(c) Repeating the above procedure [Subpart (a)] in a similar manner and substituting a stoichiometrically equivalent amount of R-3-(2-methoxyphenoxy)-2,3-epoxide for 3-(2-methoxyphenoxy)-2,3-epoxide, one obtains the corresponding R-1-[3-(2-methoxyphenoxy)-2-hydroxypropyl]piperazine.

(d) Repeating the above procedure [Subpart (a)] in a similar manner and substituting a stoichiometrically equivalent amount of one of the R-substituted phenoxy-2,3-epoxides named of Preparation A [Subpart (b)] for 1-(2-methoxyphenoxy)-2,3-epoxypropane, one obtains the corresponding R-[3-(substituted-phenoxy)-2-hydroxypropyl]piperazine.

(e) Repeating the above procedure [Subpart (a)] in a similar manner and substituting a stoichiometrically equivalent of S-1-(2-methoxyphenoxy)-2,3-epoxypropane for 1-(2-methoxyphenoxy)-2,3-epoxypropane, one obtains the corresponding S-1-[3-(2-methoxyphenoxy)-2-hydroxypropyl]piperazine.

(f) Repeating the above procedure [Subpart (a)] in a similar manner and substituting a stoichiometrically equivalent of any one of the S-1-(substituted phenoxy)-2,3-epoxypropanes in Preparation A [Subpart (d)] for 1-(substituted phenoxy)-2,3-epoxypropane, one obtains the corresponding S-1-(substituted-phenoxy)-2-hydroxypropyl]piperazine.

(g) Repeating the above procedure [Subpart (a)] in a similar manner and substituting a stoichiometrically equivalent amount of a mixture of any one of the R- and S-unsubstituted or aryl substituted-phenoxy-2,3-epoxides of Preparation A [Subparts (e) or (f)] for 1-(2-methoxyphenoxy)-2,3-epoxypropane, one obtains the corresponding mixture of R- and S-unsubstituted or aryl substituted-phenoxy-2-hydroxypropyl]piperazine.

Example 1

Preparation of 1-[3-(2-Methoxyphenoxy)-2-hydroxypropyl]-4-[(2,6-dimethylphenyl)aminocarbonylmethyl]piperazine (Reaction Sequence 1)

(a) The [(2,6-dimethylphenyl)aminocarbonylmethyl]chloride from Preparation B [Subpart (a)] (12.9 g, 65 mmoles) and 1-[3-(2-methoxyphenoxy)-2-hydroxypropyl]piperazine from Preparation D [Subpart (a)] (15 g, 65 mmoles) are mixed in 100 ml of dimethylformamide. The mixture is stirred at 65°C to dissolve the components, and then at 90°C overnight. The entire mixture is added to water and acidified with hydrochloric acid. The resulting homogeneous mixture is washed with ether, and then made basic with ammonia, and extracted with three portions of methylene chloride. The methylene chloride extracts, which contained the product, are washed with water twice, and then evaporated to 28 g of an oil. The oil is purified by chromatographing with 500 g of silica gel with 5% methanol in methylene chloride. The 20 g of yellow oil which are obtained were dissolved in methanol and crystallized by the addition of hydrochloric acid. Precipitation is completed by addition of ether and 16 g of the product, 1-[3-(2-methoxyphenoxy)-2-hydroxypropyl]-4-[(2,6-dimethylphenyl)aminocarbonylmethyl]piperazine, is obtained as an oil.

Because the 1-[3-(2-methoxyphenoxy)-2-hydroxypropyl]piperazine from Preparation D has undefined stereochemistry at the carbon atom at the 2 chain position, this compound and the substituted compounds of Subparts (b), (c) and (d) below are obtained as a mixture of the R- and S- isomers.

(b) Similarly, proceeding as in Subpart (a) above but substituting a stoichiometrically equivalent amount of any one of the substituted chloride compounds prepared in Preparation C above for 1-[(2,6-dimethylphenyl)aminocarbonylmethyl]chloride, there is obtained the corresponding 1-[3-(2-methoxyphenoxy)-2-hydroxypropyl]-4-[(substituted-phenyl)aminocarbonylmethyl]piperazine.

An exemplary compound is

1-[3-(2-methoxyphenoxy)-2-hydroxypropyl]-4-[(2,4,6-trimethylphenyl)aminocarbonylmethyl]piperazine;

(c) Similarly, proceeding as in Subpart (a) above but substituting a stoichiometrically equivalent amount of any one of the substituted piperazine compounds described in Preparation D [Subpart (b)] above for 2-[(phenoxy)-2-hydroxypropyl]piperazine, there is obtained the corresponding 1-[3-(substituted-phenoxy)-2-hydroxypropyl]-4-[(2,6-dimethylphenyl)aminocarbonylmethyl]piperazine.

Exemplary compounds include the following:

1-[3-(4-methylphenoxy)-2-hydroxypropyl]-4-[(2,6-dimethylphenyl)aminocarbonylmethyl]piperazine;
 1-[3-(4-methoxyphenoxy)-2-hydroxypropyl]-4-[(2,6-dimethylphenyl)aminocarbonylmethyl]piperazine;
 1-[3-(4-chlorophenoxy)-2-hydroxypropyl]-4-[(2,6-dimethylphenyl)aminocarbonylmethyl]piperazine;
 1-[3-(3-methylphenoxy)-2-hydroxypropyl]-4-[(2,6-dimethylphenyl)aminocarbonylmethyl]piperazine;
 1-[3-(3-methoxyphenoxy)-2-hydroxypropyl]-4-[(2,6-dimethylphenyl)aminocarbonylmethyl]piperazine;
 1-[3-(3-chlorophenoxy)-2-hydroxypropyl]-4-[(2,6-dimethylphenyl)aminocarbonylmethyl]piperazine;
 1-[3-(2,4-dimethylphenoxy)-2-hydroxypropyl]-4-[(2,6-dimethylphenyl)aminocarbonylmethyl]piperazine;
 1-[3-(2-acetylphenoxy)-2-hydroxypropyl]-4-[(2,6-dimethylphenyl)aminocarbonylmethyl]piperazine;
 1-[3-(4-aminocarbonylmethylphenoxy)-2-hydroxypropyl]-4-[(2,6-dimethylphenyl)aminocarbonylmethyl]piperazine; or

1-[3-(1-naphthoxy)-2-hydroxypropyl]-4-[(2,6-dimethylphenyl)aminocarbonylmethyl]piperazine.

(d) Similarly, proceeding as in [Subpart (a)] above but substituting a stoichiometrically equivalent amount of any one of the substituted chloride compounds described in Preparation B above for 1-[(2,6-dimethylphenyl)aminocarbonylmethyl]chloride and also substituting a stoichiometrically equivalent amount of any one of the substituted piperazine compounds described in Preparation D [Subpart (b)] above for 1-[3-(2-methoxyphenoxy)-2-hydroxypropyl]piperazine, there is obtained the corresponding 1-[3-(substituted-phenoxy-2-hydroxypropyl)-4-[(substituted-phenyl)aminocarbonylmethyl]piperazine.

Exemplary compounds are as follows:

1-[3-(4-methoxyphenoxy)-2-hydroxypropyl]-4-[(2,4,6-trimethylphenyl)aminocarbonylmethyl]-piperazine;
 1-[3-(4-n-butylthiophenoxy)-2-hydroxypropyl]-4-[(2,6-dimethylphenyl)aminocarbonylmethyl]-piperazine;
 1-[3-(2-methyl-3,4-dichlorophenoxy)-2-hydroxypropyl]-4-[(2,6-dimethylphenyl)aminocarbonylmethyl]-piperazine;
 1-[3-(2,3,4,5-tetrachlorophenoxy)-2-hydroxypropyl]-4-[(2,6-dimethylphenyl)aminocarbonylmethyl]-piperazine;
 1-[3-(2-methyl-5-chlorophenoxy)-2-hydroxypropyl]-4-[(2,6-dimethylphenyl)aminocarbonylmethyl]-piperazine;
 1-[3-(4-n-butylsulfinylphenoxy)-2-hydroxypropyl]-4-[(2,6-dimethylphenyl)aminocarbonylmethyl]-piperazine;
 1-[3-(4-n-butylsulfonylphenoxy)-2-hydroxypropyl]-4-[(2,6-dimethylphenyl)aminocarbonylmethyl]-piperazine;
 1-[3-(2,4-dimethylphenoxy)-2-hydroxypropyl]-4-[(2,6-dimethylphenyl)aminocarbonylmethyl]-piperazine;
 1-[3-(1-naphthoxy)-2-hydroxypropyl]-4-[(2,6-dimethylphenyl)aminocarbonylmethyl]piperazine;
 1-[3-(2-methoxyphenoxy)-2-hydroxypropyl]-4-[(2,6-dimethylphenyl)aminocarbonyl-1-methyl]-piperazine;
 1-[3-(2-methoxyphenoxy)-2-hydroxypropyl]-4-[N-methyl-N-(2,6-dimethylphenyl)aminocarbonyl-1-methyl]piperazine;
 1-[3-(2-methoxyphenoxy)-2-hydroxypropyl]-4-[N-n-butyl-N-(2,6-dimethylphenyl)aminocarbonyl-1-methyl]piperazine;
 1-[3-(2-methoxyphenoxy)-2-hydroxypropyl]-4-[(2,6-dimethylphenyl)aminocarbonyl-1-n-pentyl]piperazine;
 1-[3-(2-methoxyphenoxy)-2-hydroxypropyl]-4-[N-methyl-N-(2,6-dimethylphenyl)aminocarbonyl-1-n-pentyl]piperazine;
 1-[3-(2-methoxyphenoxy)-2-hydroxypropyl]-4-[N-n-butyl-N-(2,6-dimethylphenyl)aminocarbonyl-1-n-pentyl]piperazine;

(e) Similarly, proceeding as in Subpart (a) above but substituting a stoichiometrically equivalent of R- or any one of the substituted R-1-phenoxy-2-hydroxypropyl]piperazine compounds described above in Preparation D [Subpart (d)] for 1-[3-(2-methoxyphenoxy)-2-hydroxypropyl]piperazine, and also substituting a stoichiometrically equivalent of any one of the substituted phenyl aminocarbonylmethyl chloride compounds described in Preparation B above for 1-[(2,6-dimethylphenyl)aminocarbonylmethyl]chloride, there is obtained the corresponding R-1-[3-(substituted-phenoxy-2-hydroxypropyl)-4-[(substituted phenyl)aminocarbonylmethyl]piperazine.

(f) Similarly, proceeding as in Subpart (a) above, but substituting the appropriately substituted R-isomer piperazine for 1-[3-(2-methoxyphenoxy)-2-hydroxypropyl]piperazine, the following compounds having the R-configuration are prepared:

1-[3-(2-methylphenoxy)-2-hydroxypropyl]-4-[(2,6-dimethylphenyl)aminocarbonylmethyl]piperazine;
 1-[3-(2-methoxyphenoxy)-2-hydroxypropyl]-4-[(2,6-dimethylphenyl)aminocarbonylmethyl]piperazine;
 1-[3-(2-chlorophenoxy)-2-hydroxypropyl]-4-[(2,6-dimethylphenyl)aminocarbonylmethyl]piperazine;
 1-[3-(3-methylphenoxy)-2-hydroxypropyl]-4-[(2,6-dimethylphenyl)aminocarbonylmethyl]piperazine;
 1-[3-(3-methoxyphenoxy)-2-hydroxypropyl]-4-[(2,6-dimethylphenyl)aminocarbonylmethyl]piperazine;
 1-[3-(3-chlorophenoxy)-2-hydroxypropyl]-4-[(2,6-dimethylphenyl)aminocarbonylmethyl]piperazine;

and

1-[3-(2,4-dimethylphenoxy)-2-hydroxypropyl]-4-[(2,6-dimethylphenyl)aminocarbonylmethyl]-piperazine.

Additional exemplary compounds which may have the R-form are named in Subparts (b), (c), (d) and (e) of this example.

(g) Similarly, proceeding as in Subpart (a) above substituting a stoichiometrically equivalent amount of S- isomer or any one of the substituted S- isomers of 3-(substituted-phenoxy)-2-hydroxypropyl]piperazine compounds described in Preparation D [Subpart (f)] for 1-[3-(2-methoxyphenoxy)-2-hydroxypropyl]piperazine and also substituting a stoichiometrically equivalent amount of any one of the substituted phenyl aminocarbonylmethyl chloride compounds described in Preparation B [Subpart (b)] above for 1-[(2,6-dimethylphenyl)aminocarbonylmethyl]chloride, there is obtained the corresponding S-1-[3-(substituted-phenoxy)-2-hydroxypropyl]-4-(substituted-phenyl)aminocarbonylmethyl]piperazine.

Additional exemplary compounds which may have the R- and S- forms as a mixture are named in

Subparts (b), (c), (d), (e), and (f) of this example.

(h) Similarly, proceeding as in Subpart (a) above substituting a stoichiometrically equivalent amount of a mixture of R- and S- isomers or anyone of the substituted R- and S- 1-[3-(substituted-phenoxy)-2-hydroxypropyl]piperazine compounds described in Preparation D [Subpart (g)] for 1-[3-(2-methoxyphenoxy)-2-hydroxypropyl]piperazine and also substituting a stoichiometrically equivalent of any one of the substituted phenyl aminocarbonylmethyl chloride compounds described in Preparation B [Subpart (b)] above for 1-[(2,6-dimethylphenyl)aminocarbonylmethyl]chloride, there is obtained the corresponding mixture of R- and S-1-[3-(substituted phenoxy-2-hydroxypropyl)-4-(substituted phenyl)aminocarbonylmethyl]piperazine.

Additional exemplary compounds which may have the R- and S- forms as a mixture are named in Subparts (b), (c), (d), (e); and (f) of this example.

Example 2

Preparation of 1-[3-(2-methoxyphenoxy)-2-hydroxypropyl]-4-[(2,6-dimethylphenyl)aminocarbonylmethyl]piperazine (Reaction Sequence 2)

(a) 1-(2-Methoxyphenoxy)-2,3-epoxypropane (2.0 g) from Preparation A and 4-[(2,6-dimethylphenyl)aminocarbonylmethyl]piperazine (2.5 g) were dissolved in 20 ml of methanol and 40 ml of toluene. The solution was refluxed for 5 hours evaporated and chromatographed on silica gel using 5% methanol/methylene chloride as eluent. Excess hydrochloric acid in methanol was added and the dihydrochloride salt was formed and recovered from methanol/ether as a white powder, 3 g, mp 164—166°C [hydrate(1H₂O)].

(a)' In an alternative procedure, 1-(2-Methoxyphenoxy)-2,3-epoxypropane (3.78 g) from Preparation A and 4-[(2,6-dimethylphenyl)aminocarbonylmethyl]piperazine (4.94 g) were dissolved in isopropanol (25 ml) and the resulting solution was heated under reflux for 3 hours. The hot solution was filtered and then made acidic with methanolic hydrogen chloride. The mixture was heated on a steam bath and crystallization was induced by scratching the inside of the flask. After cooling, the dihydrochloride salt was filtered off, 7.3 g, mp 224—225°C.

Anal for C₂₄H₃₅N₃O₄Cl₂ (0.5 H₂O);

Calcd: C, 56.58; H, 7.12; N, 8.25.

Found: C, 56.38; H, 7.27; N, 8.11.

¹H NMR (DMSO—D₆) δ 2.19 (s, 6H), 3.30—3.55 (m, 2H, CH₂N), 3.78 (s, 3H, OCH₃), 3.60—3.85 (m, 8H, piperazine CH₂), 3.90—4.08 (m, 2H, OCH₂), 4.35 (s, 2H, NCH₂CO), 4.45 (m, 1H, COH), 6.85—7.08 (m, 3H), 7.10 (s, 4H), 10.32 (s, 1H, NH).

Because the 1-(2-methoxyphenoxy)-2,3-epoxypropane from Preparation A [Subpart (a)] has undefined stereochemistry at the carbon atom at position 2 of the ring, this compound and the substituted compounds of Subparts (b), (c) and (d) below are obtained as a mixture of the R- and S- forms.

(b) Similarly, proceeding as in Subpart (a) above but substituting a stoichiometrically equivalent amount of any one of the substituted phenyl piperazine compounds described in Preparation B above for 1-[(2,6-dimethylphenyl)aminocarbonylmethyl]piperazine, there is obtained the corresponding 1-[3-(2-methoxyphenoxy)-2-hydroxypropyl]-4-[(substituted phenyl)aminocarbonylmethyl]piperazine.

An exemplary compound is named in Example 1 [Subpart (b)] above.

(c) Similarly, proceeding as in Subpart (a) above but substituting stoichiometrically equivalent amount of any one of the substituted phenoxy epoxide compounds described in Preparation A, [Subpart (b)] above for epoxide, there is obtained the corresponding 1-[3-(substituted-phenoxy)-2-hydroxypropyl]-4-[(2,6-dimethylphenyl)aminocarbonylmethyl]piperazine.

Exemplary compounds are named in Example 1 above.

(d) Similarly, proceeding as in Subpart (a) above but substituting a stoichiometrically equivalent of any one of the substituted phenyl piperazine compounds described in Preparation C above for 1-[(2,6-dimethylphenyl)aminocarbonylmethyl]piperazine, and substituting a stoichiometrically equivalent of any one of the substituted phenoxy epoxides described in Preparation A above for 1-(2-methoxyphenoxy)-2,3-epoxypropane, there is obtained the corresponding 1-[3-(substituted phenoxy-2-hydroxypropyl)-4-[(substituted phenyl)aminocarbonylmethyl]piperazine.

Exemplary compounds are described in Example 1 [Subpart (d)] above and hereinbelow:

1-[3-(2-methoxyphenoxy)-2-hydroxypropyl]-4-[(2,4,6-trimethylphenyl)aminocarbonylmethyl]piperazine.

(e) Similarly, proceeding as in Subpart (a) above but substituting a stoichiometrically equivalent of R- or any one of the substituted R-[1-(phenoxy)-2,3-epoxypropane, and also substituting a stoichiometrically equivalent amount of any one of the substituted phenyl piperazine compounds described in Preparation C above for 1-[(2,6-dimethylphenyl)aminocarbonylmethyl]piperazine, there is obtained the corresponding R-3-[substituted-phenoxy)-2-hydroxypropyl]-4-[(substituted phenyl)aminocarbonylmethyl]piperazine.

Exemplary compounds of the R- form are named in Example 1, Subparts (b), (c) and (d) above.

(f) Similarly, proceeding as in Subpart (a) above but substituting a stoichiometrically equivalent amount of S- or any one of the S-[1-(optionally substituted phenoxy)-2,3-epoxypropane compounds described in Preparation D above for 1-(2-methoxyphenoxy)-2,3-epoxypropane, and also substituting a stoichiometrically equivalent amount of any one of the substituted phenylaminocarbonyl chloride compounds described in Preparation B [Subpart (b)] above for 1-[(2,6-dimethylphenyl)aminocarbonyl-

methyl]chloride, there is obtained the corresponding S-[2-(substituted phenoxy)-2-hydroxypropyl]-4-[(substituted phenyl)aminocarbonylmethyl]piperazine.

(g) Exemplary compounds of the S- form are described in Example 1, Subparts (b), (c) and (d) above.

Example 2A

(i) Preparation of S-1-[3-(2-methoxyphenoxy)-2-hydroxypropyl]-4-[(2,6-dimethylphenyl)aminocarbonylmethyl]piperazine

(a) Preparation of S-1-(2-methoxyphenoxy)-2,3-epoxypropane

(R)-2,2-Dimethyl-1,3-dioxolane-4-methanol (Aldrich) (10 g) was converted to the tosylate with p-toluenesulfonyl chloride in pyridine in the usual manner. The tosylate was added to a solution of 2-methoxyphenol (15 g) and potassium *tert*-butoxide (13.4 g) in DMF (100 ml) and the resulting mixture was stirred for 3 hours at 70°C. The cooled mixture was diluted with water and the product recovered by ether extraction. This product was dissolved in 50 ml of water, 50 ml of acetone, and 5 ml of hydrochloric acid and the resulting mixture was heated under reflux for 30 minutes. The mixture was evaporated under reduced pressure to afford a solid which was washed with ether and filtered to give 12 g of diol ($[\alpha]_D^{25}=9.07^\circ$, CH₃OH), mp 96–97°.

A solution of this diol (11.3 g) in 80 ml of pyridine was cooled to –5°C and methane-sulfonyl chloride (4.6 ml) was added dropwise. The mixture was added to water and extracted with ether. The ether was washed with 5% HCl, water, and brine, and evaporated to a residue that was dissolved in 50 ml of THF. Potassium *tert*-butoxide was added in small portions until TLC analysis showed complete reaction. Water was added and ether extraction afforded a crude product which was purified by silica gel chromatography (50% ether-hexane) to afford the S-epoxide, 4.9 g ($[\alpha]_D^{25}=12.2^\circ$, CH₃OH).

(b) S-1-[3-(2-methoxyphenoxy)-2-hydroxypropyl]-4-[(2,6-dimethylphenyl)aminocarbonylmethyl]piperazine was prepared from the S-epoxide in the same manner as used for the racemic compound in Example 2(a)' above, m.pt. (as dihydrochloride) 226–230°C, $[\alpha]_D^{25}=-10.3^\circ$ (CH₃OH).

Anal. for C₂₄H₃₅N₃O₄Cl₂

Calcd: C, 57.60; H, 7.05; N, 8.39.

Found: C, 57.68; H, 7.05; N, 8.22.

(ii) Preparation of R-1-[3-(2-methoxyphenoxy)-2-hydroxypropyl]-4-[(2,6-dimethylphenyl)aminocarbonylmethyl]piperazine

(a) Preparation of R-1-(2-methoxyphenoxy)-2,3-epoxypropane.

R-1-(2-methoxyphenoxy)-2,3-epoxypropane was prepared in the manner described in Caroon et al., J. Med. Chem. 24, 1320 (1981).

(b) R-1-[3-(2-methoxyphenoxy)-2-hydroxypropyl]-4-[(2,6-dimethylphenyl)aminocarbonylmethyl]piperazine was prepared from the R-epoxide in the same manner as used for the racemic compound in Example 2(a)' above, m.pt. (as dihydrochloride) 220–222°C, $[\alpha]_D^{25}=+9.84$ (CH₃OH).

Example 28

Preparation of 1-[3-(4-dimethylaminophenoxy)-2-hydroxypropyl]-4-[(2,6-dimethylphenyl)aminocarbonylmethyl]piperazine

(a) 1-(4-nitrophenoxy)-2,3-epoxypropane was prepared for 4-nitrophenol in the manner used in Preparation A(a).

(b) 1-[3-(4-nitrophenoxy)-2-hydroxypropyl]-4-[(2,6-dimethylphenyl)aminocarbonylmethyl]piperazine was prepared from 1-(4-nitrophenoxy)-2,3-epoxypropane and 4-[(2,6-dimethylphenyl)aminocarbonylmethyl]piperazine in the manner used in Example 2(a).

(c) This 4-nitro compound was then reduced to the corresponding 4-amino compound by hydrogenation in presence of PtO₂ with methanol as reaction medium. The reaction was complete after one hour, then formaldehyde was added in excess to the medium which was heated under hydrogen at 40°C for two hours. Solvents were then evaporated, the residue purified on column chromatography (silicagel) using MeOH/CH₂Cl₂ (1/9) as eluant, to give the title compound. The trichloride salt of the title compound was then prepared in the manner used in Example 2(a), m.pt. 192°C.

(d) Alternatively, the title compound may be prepared in similar manner but using 4-dimethylaminophenol as starting material.

Example 3

(Preparation of Compounds of formula I)

(a) A solution of 0.70 g of 1-[(2,6-dimethylphenyl)aminocarbonylmethyl]piperazine and 0.71 g of the R-1-phenoxy-2,3-epoxypropane in 20 ml of toluene and 20 ml of methanol is refluxed for 12 hours. Evaporation and chromatography of the residue on silica gel with 10% methanol-methylene chloride gives 0.5 g of R-1-[3-phenoxy-2-hydroxypropyl]-4-[(2,6-dimethylphenyl)aminocarbonylmethyl]piperazine which is then dissolved in methanol containing excess HCl and precipitated with ether to give the di HCl salt.

(b) Similarly, proceeding as in the Subpart (a) above, but substituting the appropriate 1-(substituted arylaminocarbonyl)piperazine from Preparation C for 4-[(2,6-dimethylphenyl)aminocarbonylmethyl]piperazine, exemplary compounds are prepared as the dihydrochloride salts.

Example 4

Preparation of Salts of Compounds of formula I

(a) A solution of 0.70 g of 1-[(2,6-dimethylphenyl)aminocarbonylmethyl]piperazine and 0.71 g of the 1-phenoxy-2,3-epoxypropane in 20 ml of toluene and 20 ml of methanol is combined and heated at reflux temperature for 12 hours. Evaporation and chromatography of the residue on silica gel with 10% methanol-methylene chloride gives 0.5 g of 1-[3-phenoxy-2-hydroxypropyl]-4-[(2,6-dimethylphenyl)aminocarbonylmethyl]piperazine which is then dissolved in methanol containing excess HCl and precipitated with ether to give the di HCl salt, mp 193—5°C.

(b) Similarly, proceeding as in Subpart (a) above, but substituting the appropriate 1-(substituted arylaminocarbonyl)piperazine from Preparation C for 1-[(2,6-dimethylphenyl)aminocarbonylmethyl]piperazine, the exemplary compounds are prepared as the dihydrochloride salts.

Example 5

(a) Similarly, the compounds of formula I are produced using any of the procedures of Examples 1, 2, 3 or 4 above and the following compounds may be prepared as the hydrochloride or dihydrochloride salts using the procedure of Examples 4 or 6. If desired, the following exemplary compounds and salts may be converted into the free base form by the procedure in Examples 7 and 10 or to another salt by following the procedure of Example 8.

1-[3-(2-cyanophenoxy)-2-hydroxypropyl]-4-[(2,6-dimethylphenyl)aminocarbonylmethyl]piperazine and dihydrochloride, di-HCl, mp 213—215°C;
 1-[3-(2-methoxyphenoxy)-2-hydroxypropyl]-4-[(2,6-dimethylphenyl)aminocarbonylmethyl]piperazine and dihydrochloride salt, R- di-HCl, mp 220—222°C;
 1-[3-(4-chlorophenoxy)-2-hydroxypropyl]-4-[(2,6-dimethylphenyl)aminocarbonylmethyl]piperazine and dihydrochloride, R,S- di-HCl, mp 205°C;
 1-[3-(phenoxy)-2-hydroxypropyl]-4-[(2,6-dimethylphenyl)aminocarbonylmethyl]piperazine and dihydrochloride, R,S- di-HCl, mp 195°C;
 1-[3-(3,4,5-trimethoxyphenoxy)-2-hydroxypropyl]-4-[(2,6-dimethylphenyl)aminocarbonylmethyl]piperazine and dihydrochloride, R,S- di-HCl, mp 210°C;
 1-[3-(2-acetylphenoxy)-2-hydroxypropyl]-4-[(2,6-dimethylphenyl)aminocarbonylmethyl]piperazine and dihydrochloride, R,S- di-HCl, mp 195°C;
 1-[3-(4-aminocarbonylmethylphenoxy)-2-hydroxypropyl]-4-[(2,6-dimethylphenyl)aminocarbonylmethyl]piperazine and dihydrochloride salt, R,S- di-HCl, mp 148—150°C;
 1-[3-(2-isopropoxyphenoxy)-2-hydroxypropyl]-4-[(2,6-dimethylphenyl)aminocarbonylmethyl]piperazine and dihydrochloride, R,S- di-HCl, mp 180°C;
 1-[3-(1-naphthoxy)-2-hydroxypropyl]-4-[(2,6-dimethylphenyl)aminocarbonylmethyl]piperazine and dihydrochloride, R,S- di-HCl, mp 154—156°C;
 1-[3-(2-acetylphenoxy)-1-[3-(4-n-butanoylphenoxy)-2-hydroxypropyl]-4-[(2,6-dimethylphenyl)aminocarbonylmethyl]piperazine and dihydrochloride;
 1-[3-(2-acetylphenoxy)-1-[3-(4-N,N-dimethylaminophenoxy)-2-hydroxypropyl]-4-[(2,6-dimethylphenyl)aminocarbonylmethyl]piperazine and dihydrochloride;
 1-[3-(2-acetylphenoxy)-1-[3-(4-N,N-di-n-butylaminophenyl)-2-hydroxypropyl]-4-[(2,6-dimethylphenyl)aminocarbonylmethyl]piperazine and dihydrochloride;

(b) Similarly, proceeding as in Subpart (a) above, but substituting an equivalent amount of R- or S-1-(phenoxy)-2,3-epoxypropane for 1-(2-methoxyphenoxy)-2,3-epoxypropane, there is obtained the corresponding salt derivatives having the R- or S- configuration, respectively.

(c) Similarly, proceeding as in Subpart (a) above, but substituting a stoichiometrically equivalent amount of R- or S-1-(optionally substituted phenylthio)-2,3-epoxypropane for R-1-(2-methoxyphenoxy)-2,3-epoxypropane, there is obtained the corresponding salt derivatives having the corresponding R- or S-orientation, respectively.

Example 6

Conversion of Free Base to Salt

8.0 g of 1-[3-(2-methoxyphenoxy)-2-hydroxypropyl]-4-[(2,6-dimethylphenyl)aminocarbonylmethyl]piperazine is dissolved in methanol and acidified with methanolic hydrochloric acid. The precipitate is washed with ether to give 7.0 g of the dihydrochloride salt of 1-[3-(2-methoxyphenoxy)-2-hydroxypropyl]-4-[(2,6-dimethylphenyl)aminocarbonylmethyl]piperazine, mp 175—6°C.

In similar manner, all compounds of formula I in base form prepared in accordance with Examples 1, 2, 3 or 4 can be converted to the corresponding pharmaceutically acceptable acid addition salts by treatment with the appropriate acid, for example, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, acetic acid, propionic acid, glycolic acid, pyruvic acid, oxalic acid, malonic acid, succinic acid, malic acid, maleic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid and the like.

Example 7

Conversion of Salt to Free Base

1.0 g of 1 - [3 - (2 - methoxyphenoxy) - 2 - hydroxypropyl] - 4 - [(2,6 - dimethylphenyl)aminocarbonylmethyl]piperazine 2HCl suspended in 50 ml of ether is stirred with excess dilute aqueous potassium carbonate solution until the salt is completely dissolved. The organic layer is then separated, washed twice with water, dried over magnesium sulfate and evaporated to yield 1 - [3 - (2 - methoxyphenoxy) - 2 - hydroxypropyl] - 4 - [(2,6 - dimethylphenyl)aminocarbonylmethyl]piperazine as the free base.

In a similar manner, the acid addition salts prepared in accordance with Example 6 are converted to the corresponding free base.

Example 8

Direct Interchange of Acid Addition Salts

1 - [3 - (2 - methoxyphenoxy) - 2 - hydroxypropyl] - 4 - [(2,6 - dimethylphenyl)aminocarbonylmethyl]piperazine acetate (1.0 g) is dissolved in 50 ml 50% aqueous sulfuric acid, and the solution evaporated to dryness. The product is suspended in ethanol and filtered, air dried and recrystallized from methanol/acetone to yield 1 - [3 - (2 - methoxyphenoxy) - 2 - hydroxypropyl] - 4 - [(2,6 - dimethylphenyl)aminocarbonylmethyl]piperazine 2HSO₄.

Example 9

(Preparation of Esters and Dihydrochloride Salts of Formula I)

(a) One g of 1 - [3 - (2 - methoxyphenoxy) - 2 - hydroxypropyl] - 4 - [(2,6 - dimethylphenyl)aminocarbonylmethyl]piperazine is dissolved in 25 ml of pyridine and cooled in an ice bath to 0—5°C. Acetic anhydride (0.6 g) is slowly added and the reaction is stirred for 2 hours. After the addition of 100 ml of water, the reaction mixture is extracted twice with 100 ml portions of diethylether. After combining, the ether extract is washed twice with 100 ml of water and evaporated to dryness to produce 1 - [3 - (2 - methoxyphenoxy) - 2 - acetoxypyl] - 4 - [(2,6 - dimethylphenyl)aminocarbonylmethyl]piperazine as an oil.

(b) Repeating the above procedure [Subpart (a) of this Example in a similar manner and substituting a stoichiometrically equivalent amount of propionic anhydride; n-butyric anhydride; n-hexanoic anhydride; n-octanoic anhydride; or n-dodecanoic anhydride for acetic anhydride, there are obtained the following piperazines.

1-[3-(2-methoxyphenoxy)-2-propanoyloxypropyl]-4-[(2,6-dimethylphenyl)aminocarbonylmethyl]-piperazine;

1-[3-(2-methoxyphenoxy)-2-n-butanoyloxypropyl]-4-[(2,6-dimethylphenyl)aminocarbonylmethyl]-piperazine;

1-[3-(2-methoxyphenoxy)-2-n-hexanoyloxypropyl]-4-[(2,6-dimethylphenyl)aminocarbonylmethyl]-piperazine;

1-[3-(2-methoxyphenoxy)-2-n-dodecanoyloxypropyl]-4-[(2,6-dimethylphenyl)aminocarbonylmethyl]-piperazine; or

1-[3-(2-methoxyphenoxy)-2-n-dodecanoyloxypropyl]-4-[(2,6-dimethylphenyl)aminocarbonylmethyl]piperazine.

(c) Repeating the above procedure [Subpart (a) of this example in a similar manner and substituting a stoichiometrically equivalent amount of alkyl anhydride for acetic anhydride and 1 - [3 - (optionally substituted phenoxy) - 2 - hydroxypropyl] - 4 - [(optionally substituted phenyl)aminocarbonylmethyl]piperazine for 1 - [3 - (2 - methoxyphenoxy) - 2 - hydroxypropyl] - 4 - [(2,6 - dimethylphenyl)aminocarbonylmethyl]piperazine, there is obtained the corresponding 1 - [3 - (optionally substituted phenoxy) - 2 - alkanoyloxy - propyl] - 4 - [(optionally substituted phenyl)aminocarbonyl - methyl]piperazine.

(d) The compounds described in Subparts (a), (b) or (c) of this Example when treated with excess hydrochloric acid as described in Example 8 produce the corresponding 1 - [3 - (optionally substituted phenoxy) - 2 - alkanoyloxypropyl] - 4 - [(optionally substituted phenyl)aminocarbonylmethyl]piperazine dihydrochloride.

In all of the reactions described by Subparts (a), (b), (c) and (d) of this Example, optionally substituted thiophenoxy compounds may be substituted for the phenoxy compounds, and the stereochemistry of the compound of formula I is not changed.

Example 10

A solution of 3.5 g of 1 - [3 - (2 - methoxyphenoxy) - 2 - hydroxypropyl] - 4 - [(2,6 - dimethylphenyl)aminocarbonylmethyl]piperazine dihydrochloride salt in water (50 ml) is adjusted to pH 12 with ammonium hydroxide solution and extracted with methylene chloride. The methylene chloride is evaporated to afford 3 g of 1 - [3 - (2 - methoxyphenoxy) - 2 - hydroxypropyl] - 4 - [(2,6 - dimethylphenyl)aminocarbonylmethyl]piperazine as the free base.

In a similar manner, the acid addition salts prepared in accordance with Examples 6 and 8 are converted to the corresponding free base.

0 126 449

Example 11

The following example illustrates the preparation of representative pharmaceutical formulations containing an active compound of formula I, e.g., 1 - [3 - (2 - methoxyphenoxy) - 2 - hydroxypropyl] - 4 - [(2,6 - dimethylphenyl)aminocarbonylmethyl]piperazine.

I.V. Formulation

Active compound	0.14 g
Propylene glycol	20.0 g
POLYETHYLENE GLYCOL 400	20.0 g
TWEEN® 80	1.0 g
0.9% Saline solution	100.0 ml

In Examples 11 through 17, the active ingredient is 1 - [1 - (phenoxy) - 2 - hydroxypropyl] - 4 - [(2,6 - dimethylphenyl)aminocarbonylmethyl]piperazine dihydrochloride. Other compounds of formula I and the pharmaceutically acceptable salts thereof may be substituted therein.

Example 12

Ingredients	Quantity per tablet, mgs.
Active ingredient	25
cornstarch	20
lactose, spray-dried	153
magnesium stearate	2

The above ingredients are thoroughly mixed and pressed into single scored tablets.

Example 13

Ingredients	Quantity per capsule, mgs.
Active ingredient	100
lactose, spray-dried	148
magnesium stearate	2

The above ingredients are mixed and introduced into a hard-shell gelatin capsule.

Example 14

Ingredients	Quantity per tablet, mgs.
Active ingredient	1
cornstarch	50
lactose	145
magnesium stearate	5

The above ingredients are mixed intimately and pressed into single scored tablets.

O 126 449**Example 15**

	<u>Ingredients</u>	<u>Quantity per capsule, mgs.</u>
5	Active ingredient	108
	lactose	15
10	cornstarch	25
	magnesium stearate	2

15 The above ingredients are mixed and introduced into a hard-shell gelatin capsule.

Example 16

	<u>Ingredients</u>	<u>Quantity per capsule, mgs.</u>
20	Active ingredient	150
	lactose	92

25 The above ingredients are mixed and introduced into a hard-shell gelatin capsule.

Example 17

An injectable preparation buffered to a pH of 7 is prepared having the following composition:

30	<u>Ingredients</u>	
	Active ingredient	0.2 g
	KH ₂ PO ₄ buffer (0.4 M solution)	2 ml
35	KOH (1N)	q.s. to pH 7
	water (distilled, sterile)	q.s. to 20 ml

Example 18

40 An oral suspension is prepared having the following composition:

	<u>Ingredients</u>	
45	Active ingredient	0.1 g
	fumaric acid	0.5 g
	sodium chloride	2.0 g
50	methyl paraben	0.1 g
	granulated sugar	25.5 g
55	sorbitol (70% solution)	12.85 g
	Veegum K (Vanderbilt Co.)	1.0 g
	flavoring	0.035 ml
60	colorings	0.5 mg
	distilled water	q.s. to 100 ml

65

Example 19
Pharmacological Activity

The compound 1 - [3 - (2 - methoxyphenoxy) - 2 - hydroxypropyl] - 4 - [(2,6 - dimethylphenyl)-aminocarbonylmethyl]piperazine, dihydrochloride salt, was examined for anti-anginal activity.

Methodology

This was based on that of L. Szekeres, J. Pharm. Exp. Ther., Vol 196, p. 15 to 28, 1976, and was as follows:

Adult beagles of either sex (11—16 kg) were premedicated with 0.2 mg/kg acetylpromazine i.m. and anaesthetised with 30 mg/kg sodium pentobarbital i.v., intubated, ventilated artificially, and thoracotomized via a left lateral 5th intercostal approach. The left anterior descending coronary artery (LAD) was loosely snared with a ligature drawn up through a nylon guide tube to obstruct blood flow through the mid anterior ventricle wall. A transient critical stenosis effect on the arterial vascular bed perfused below the LAD was created by intermittent (but time controlled 12 min cycles) episodes of complete occlusion of the LAD with superimposed pacing of the heart at 50—70 beats/min above its resting rate. In this case for each ischaemic insult one minute following commencement of pacing the LAD was completely occluded by a reversible snare. Pacing with occlusion still applied was continued for a further 2 min. S—T segment elevations were induced in 8 epicardial electrograms as consequence of each ischaemic challenge and these effects were essentially reversible within 5—10 min when the heart was allowed to return to spontaneous beating. These S—T segment changes served as an electrophysiological indicator during the recovery phase of oxygen/metabolic debt. After discarding the first exaggerated response, a further 4—5 repeated cycles of stress pacing at 12 min intervals were required to 'condition' each heart to give reproducible control traces. The S—T segment elevations so induced were always greater than simple occlusion alone. Tests were made to determine whether pre-test treatment with cumulative i.v. doses of drug, given 5 min before pacing, could inhibit the S—T segment changes.

Results

The test compound at a dose of 5 µg/kg i.v. gave a statistically significant decrease in the S—T segment elevation.

Cardioselectivity

On other tests, the same compound was shown to have a good level of selectivity for cardiac muscle over vascular muscle, a desirable property for an anti-anginal compound.


Example 20

Toxicity

Both 1 - [3 - (2 - methoxyphenoxy) - 2 - hydroxypropyl] - 4 - [(2,6 - dimethylphenyl)aminocarbonylmethyl]piperazine, dihydrochloride salt, and its S-isomer, were separately administered to rats in a 7-day oral dosing study at doses up to 250 mg/kg per day orally. No evidence of toxic effects with either compound was observed.

Claims for the Contracting States: BE CH DE FR GB IT LI LU NL SE


1. A compound of the formula:



and the pharmaceutically acceptable esters and acid addition salts thereof, wherein:

R¹ and R⁵ are each C₁₋₄ alkyl;

R², R³ and R⁴ are each independently hydrogen, C₁₋₄ alkyl, C₁₋₄ alkoxy, cyano, trifluoromethyl, halo, C₁₋₄ alkylthio, C₁₋₄ alkyl sulfinyl or C₁₋₄ alkyl sulfonyl, an alkylamido group




wherein R¹⁶ is independently hydrogen or C₁₋₄ alkyl and R¹⁷ is C₁₋₄ alkyl, except that when R¹ is methyl, R⁴

is not methyl; or

R² and R³ together form —OCH₂O—;

R⁶, R⁷, R⁸, R⁹ and R¹⁰ are each independently hydrogen, an acyl group



wherein R¹⁵ is C₁₋₄ alkyl, aminocarbonylmethyl, phenyl, cyano, C₁₋₄ alkyl, C₁₋₄ alkoxy, trifluoromethyl, halo, C₁₋₄ alkylthio, C₁₋₄ alkyl sulfinyl or C₁₋₄ alkyl sulfonyl, di-C₁₋₄ alkyl amino; or

R⁶ and R⁷ together form —CH=CH—CH=CH—;

R⁷ and R⁸ together form —OCH₂O—;

R¹¹ and R¹² are each independently hydrogen or C₁₋₄ alkyl; and

W is oxygen or sulfur.

2. The compound of claim 1 wherein two substituents selected from R², R³ or R⁴ are hydrogen and two substituents selected from R⁶, R⁷, R⁸, R⁹ and R¹⁰ are hydrogen.

3. The compound of claim 2 wherein W is oxygen.

4. The compound of claim 3 wherein R², R³ and R⁴ are hydrogen.

5. The compound of claim 4 wherein R¹ and R⁵ are each methyl.

6. The compound of claim 5, which is 1 - [3 - phenoxy - 2 - hydroxypropyl] - 4 - [(2,6 - dimethylphenyl)aminocarbonylmethyl]piperazine, and the pharmaceutically acceptable acid addition salts thereof.

7. The compound of claim 5, which is 1 - [3 - (2 - methoxyphenoxy) - 2 - hydroxypropyl] - 4 - [(2,6 - dimethylphenyl)aminocarbonylmethyl]piperazine, and the pharmaceutically acceptable acid addition salts thereof.

8. The R isomer of the compound of claim 7, and the pharmaceutically acceptable acid addition salts thereof.


9. The S isomer of the compound of claim 7, and the pharmaceutically acceptable acid addition salts thereof.

10. A pharmaceutical composition which comprises a therapeutically effective amount of a compound of any one of the Claims 1 to 9, in admixture with a pharmaceutically acceptable excipient.

11. A compound according to any one of the claims 1 to 9, for use in the treatment of cardiovascular diseases.

12. A process for preparing a compound of formula (I) according to Claim 1, and the pharmaceutically acceptable esters and acid addition salts thereof, which process comprises reacting piperazine bearing one of the side chain arms of the compound of formula (I) with a source of the other side chain arm of the compound of formula (I); or converting a salt of a compound of formula (I) to the corresponding free base; or converting a free base compound of formula (I) to a pharmaceutically acceptable acid addition salt; or converting one salt of a compound of formula (I) to a different pharmaceutically acceptable salt of a compound of formula (I); or converting a compound of formula (I) or a salt thereof to a pharmaceutically acceptable ester; or separating a compound of formula (I) or a salt or ester thereof into a stereoisomer thereof.

13. A process according to claim 12, wherein a compound of formula (E):



wherein Ar¹ is an aryl group which may optionally be substituted by R⁶ to R¹⁰ as defined in claim 1 is reacted with a compound of formula (F):




wherein Ar² represents an optionally substituted phenyl group and X is a leaving group.

14. A process according to claim 12, wherein a compound of formula (A):



is reacted with a compound of formula (G):




(G)

wherein Ar¹ and Ar² are as defined in claim 13.

Claims for the Contracting State: AT

1. A process for preparing a compound of the formula:




(I)

and the pharmaceutically acceptable esters and acid addition salts thereof, wherein:

R¹ and R⁵ are each C₁₋₄ alkyl;


R², R³ and R⁴ are each independently hydrogen, C₁₋₄ alkyl, C₁₋₄ alkoxy, cyano, trifluoromethyl, halo, C₁₋₄ alkylthio, C₁₋₄ alkyl sulfinyl or C₁₋₄ alkyl sulfonyl, an alkylamido group



wherein R¹⁶ is independently hydrogen or C₁₋₄ alkyl and R¹⁷ is C₁₋₄ alkyl, except that when R¹ is methyl, R⁴ is not methyl; or

R² and R³ together form —OCH₂O—;

R⁶, R⁷, R⁸, R⁹ and R¹⁰ are each independently hydrogen, an acyl group



wherein R¹⁵ is C₁₋₄ alkyl, aminocarbonylmethyl, phenyl, cyano, C₁₋₄ alkyl, C₁₋₄ alkoxy, trifluoromethyl, halo, C₁₋₄ alkylthio, C₁₋₄ alkyl sulfinyl or C₁₋₄ alkyl sulfonyl, di-C₁₋₄ alkyl amino; or

R⁶ and R⁷ together form —CH=CH—CH=CH—;


R⁷ and R⁸ together form —OCH₂O—;

R¹¹ and R¹² are each independently hydrogen or C₁₋₄ alkyl; and

W is oxygen or sulfur;

which process comprises reacting piperazine bearing one of the side chain arms of the compound of formula (I) with a source of the other side chain arm of the compound of formula (I); or converting a salt of a compound of formula (I) to the corresponding free base; or converting a free base compound of formula (I) to a pharmaceutically acceptable acid addition salt; or converting one salt of a compound of formula (I) to a different pharmaceutically acceptable salt of a compound of formula (I); or converting a compound of formula (I) or a salt thereof to a pharmaceutically acceptable ester; or separating a compound of formula (I) or a salt or ester thereof into a stereoisomer thereof.

2. A process according to Claim 1, wherein a compound of formula (E):



(E)

wherein Ar¹ is an aryl group which may optionally be substituted by R⁶ to R¹⁰ as defined in claim 1 is reacted with a compound of formula (F):




wherein Ar² represents an optionally substituted phenyl group and X is a leaving group.

3. A process according to Claim 1, wherein a compound of formula (A):



is reacted with a compound of formula (G):



wherein Ar¹ and Ar² are as defined in claim 2.

4. A process according to Claim 1, 2 or 3, wherein two substituents selected from R², R³ or R⁴ are hydrogen and two substituents selected from R⁶, R⁷, R⁸, R⁹ or R¹⁰ are hydrogen.

5. A process according to Claim 4, wherein W is oxygen.

6. A process according to Claim 5, wherein R², R³ and R⁴ are hydrogen.

7. A process according to claim 6, wherein R¹ and R⁵ are each methyl.

8. A process according to claim 7, wherein 1 - [3 - phenoxy - 2 - hydroxypropyl] - 4 - [(2,6 - dimethyl - phenyl)aminocarbonylmethyl]piperazine or the pharmaceutically acceptable acid addition salts thereof are prepared.

9. A process according to claim 7, wherein 1 - [3 - (2 - methoxyphenoxy) - 2 - hydroxypropyl] - 4 - [(2,6 - dimethylphenyl)aminocarbonylmethyl]piperazine or the pharmaceutically acceptable acid addition salts thereof are prepared.

10. A process according to claim 9, wherein the R isomer of the compound or the pharmaceutically acceptable acid addition salts thereof are prepared.


11. A process according to claim 9, wherein the S isomer of the compound or the pharmaceutically acceptable acid addition salts thereof are prepared.

12. The use of a compound prepared in accordance with any one of claims 1 to 11 for the manufacture of a medicament.

13. The use according to claim 12, wherein the medicament is for use in the treatment of cardiovascular diseases.

Patentansprüche für die Vertragsstaaten: BE CH DE FR GB IT LI LU NL SE


1. Verbindung der Formel




und die pharmazeutisch annehmbaren Ester und Säureadditionssalze derselben, in welcher:

R¹ und R⁵ jeweils C₁₋₄ Alkyl bedeuten;

R₂, R₃ und R₄ jeweils unabhängig voneinander für Wasserstoff, C₁₋₄ Alkyl, C₁₋₄ Alkoxy, Cyan, Trifluormethyl, Halogen, C₁₋₄ Alkylthio, C₁₋₄ Alkylsulfinyl oder C₁₋₄ Alkylsulfonyl, eine Alkylamidogruppe



wobei R^{16} unabhängig Wasserstoff oder C_{1-4} Alkyl und R^{17} C_{1-4} Alkyl darstellt, stehen, mit der Ausnahme, daß wenn R^1 Methyl bedeutet, R^4 nicht Methyl ist; oder R^2 und R^3 zusammen $-OCH_2O-$ bilden; R^6, R^7, R^8, R^9 und R^{10} jeweils unabhängig voneinander Wasserstoff, eine Acylgruppe



wobei R^{15} C_{1-4} Alkyl darstellt, Aminocarbonylmethyl, Phenyl, Cyano, C_{1-4} Alkyl, C_{1-4} Alkoxy, Trifluormethyl, Halogen, C_{1-4} Alkylthio, C_{1-4} Alkylsulfinyl oder C_{1-4} Alkylsulfonyl, Di- C_{1-4} -alkylamino repräsentieren; oder

R^6 und R^7 zusammen $-CH=CH-CH=CH-$ bilden;

R^7 und R^8 zusammen $-OCH_2O-$ bilden;

R^{11} und R^{12} jeweils unabhängig voneinander Wasserstoff oder C_{1-4} Alkyl repräsentieren; und W für Sauerstoff oder Schwefel steht.

2. Verbindung nach Anspruch 1, in welcher zwei Substituenten, ausgewählt aus R^1, R^3 oder R^4 , Wasserstoff sind und zwei Substituenten, ausgewählt aus R^6, R^7, R^8, R^9 und R^{10} , Wasserstoff sind.

3. Verbindung nach Anspruch 2, in welcher W für Sauerstoff steht.

4. Verbindung nach Anspruch 3, in welcher R^2, R^3 und R^4 Wasserstoff bedeuten.

5. Verbindung nach Anspruch 4, in welcher R^1 und R^5 jeweils Methyl sind.

6. Verbindung nach Anspruch 5, nämlich 1 - [3 - Phenoxy - 2 - hydroxypropyl] - 4 - [(2,6 - dimethylphenyl)aminocarbonylmethyl]piperazin, und die pharmazeutisch annehmbaren Säureadditionssalze derselben.

7. Verbindung nach Anspruch 5, nämlich 1 - [3 - (2 - Methoxyphenoxy) - 2 - hydroxypropyl] - 4 - [(2,6 - dimethylphenyl)aminocarbonylmethyl]piperazin, und die pharmazeutisch annehmbaren Säureadditionssalze derselben.

8. Das R-Isomere der Verbindung nach Anspruch 7 und die pharmazeutisch annehmbaren Säureadditionssalze desselben.


9. Das S-Isomere der Verbindung nach Anspruch 7 und die pharmazeutisch annehmbaren Säureadditionssalze desselben.

10. Pharmazeutische Zusammensetzung, welche umfaßt eine therapeutisch wirksame Menge einer Verbindung nach einem der Ansprüche 1 bis 9 in Mischung mit einem pharmazeutisch annehmbaren Exipienten.

11. Verbindung nach einem der Ansprüche 1 bis 9 zur Verwendung bei der Behandlung von kardiovaskulären Krankheiten.

12. Verfahren zur Herstellung einer Verbindung der Formel (I) nach Anspruch 1 und der pharmazeutisch annehmbaren Ester und Säureadditionssalze derselben, welches Verfahren umfaßt die Umsetzung von einem der Seitenkettenarme der Verbindung der Formel (I) tragendem Piperazin mit einer Quelle für den anderen Seitenkettenarm der Verbindung der Formel (I); oder die Umwandlung eines Salzes einer Verbindung der Formel (I) in die entsprechende freie Base; oder die Umwandlung einer freien Base - Verbindung der Formel (I) in ein pharmazeutisch annehmbares Säureadditionssalz; oder die Umwandlung eines Salzes einer Verbindung der Formel (I) in ein anderes pharmazeutisch annehmbares Salz einer Verbindung der Formel (I); oder die Umwandlung einer Verbindung der Formel (I) oder eines Salzes derselben in einen pharmazeutisch annehmbaren Ester; oder die Auftrennung einer Verbindung der Formel (I) oder eines Salzes oder Esters derselben in ein Stereoisomeres derselben.

13. Verfahren nach Anspruch 12, bei welchem eine Verbindung der Formel (E):



in welcher Ar^1 für eine Arylgruppe steht, die gegebenenfalls durch R^6 bis R^{10} , wie in Anspruch 1 definiert, substituiert sein kann, mit einer Verbindung der Formel (F):




in welcher Ar^2 eine gegebenenfalls substituierte Phenylgruppe darstellt und X eine Abgangsgruppe bedeutet, umgesetzt wird.

14. Verfahren nach Anspruch 12, bei welchem eine Verbindung der Formel (A):




mit einer Verbindung der Formel (G)



in welchen Ar¹ und Ar² wie in Anspruch 13 definiert sind, umgesetzt wird.


Patentansprüche für den Vertragsstaat: AT

1. Verfahren zur Herstellung einer Verbindung der Formel:



und der pharmazeutisch annehmbaren Ester und Säureadditionssalze derselben, in welcher:


R¹ und R⁵ jeweils C₁₋₄ Alkyl bedeuten;
R², R³ und R⁴ jeweils unabhängig voneinander für Wasserstoff, C₁₋₄ Alkyl, C₁₋₄ Alkoxy, Cyan, Trifluormethyl, Halogen, C₁₋₄ Alkylthio, C₁₋₄ Alkylsulfinyl oder C₁₋₄ Alkylsulfonyl, eine Alkylamidogruppe



wobei R¹⁶ unabhängig Wasserstoff oder C₁₋₄ Alkyl und R¹⁷ C₁₋₄ Alkyl darstellt, stehen, mit der Ausnahme, daß wenn R¹ Methyl bedeutet, R⁴ nicht Methyl ist; oder

R² und R³ zusammen ---OCH₂O--- bilden;

R⁶, R⁷, R⁸, R⁹ und R¹⁰ jeweils unabhängig voneinander Wasserstoff, eine Acylgruppe



wobei R¹⁵ C₁₋₄ Alkyl darstellt, Aminocarbonylmethyl, Phenyl, Cyano, C₁₋₄ Alkyl, C₁₋₄ Alkoxy, Trifluormethyl, Halogen, C₁₋₄ Alkylthio, C₁₋₄ Alkylsulfinyl oder C₁₋₄ Alkylsulfonyl, Di-C₁₋₄-alkylamino repräsentieren; oder

R⁶ und R⁷ zusammen ---CH=CH---CH=CH--- bilden;


R⁷ und R⁸ zusammen ---OCH₂O--- bilden;

R¹¹ und R¹² jeweils unabhängig voneinander Wasserstoff oder C₁₋₄ Alkyl repräsentieren; und


W für Sauerstoff oder Schwefel steht;

welches Verfahren umfaßt die Umsetzung von einem der Seitenkettenarme der Verbindung der Formel (I) tragendem Piperazin mit einer Quelle für den anderen Seitenkettenarm der Verbindung der Formel (I); oder die Umwandlung eines Salzes einer Verbindung der Formel (I) in die entsprechende freie Base; oder die Umwandlung einer freien Base --- Verbindung der Formel (I) in ein pharmazeutisch annehmbares Säureadditionssalz; oder die Umwandlung eines Salzes einer Verbindung der Formel (I) in ein anderes pharmazeutisch annehmbares Salz einer Verbindung der Formel (I); oder die Umwandlung einer Verbindung der Formel (I) oder eines Salzes derselben in einen pharmazeutisch annehmbaren Ester; oder die Auftrennung einer Verbindung der Formel (I) oder eines Salzes oder Esters derselben in ein Stereoisomeres derselben.

2. Verfahren nach Anspruch 1, bei welchem eine Verbindung der Formel (E):



in welcher Ar¹ für eine Arylgruppe steht, die gegebenenfalls durch R⁶ bis R¹⁰, wie in Anspruch 1 definiert, substituiert sein kann, mit einer Verbindung der Formel (F):




in welcher Ar² eine gegebenenfalls substituierte Phenylgruppe darstellt und X eine Abgangsgruppe bedeutet, umgesetzt wird.

3. Verfahren nach Anspruch 1, bei welchem eine Verbindung der Formel (A):



mit einer Verbindung der Formel (G)



in welchen Ar¹ und Ar² wie in Anspruch 13 definiert sind, umgesetzt wird.

4. Verfahren nach Anspruch 1, 2 oder 3, bei welchem zwei Substituenten, ausgewählt aus R², R³ oder R⁴, Wasserstoff sind und zwei Substituenten, ausgewählt aus R⁶, R⁷, R⁸, R⁹ oder R¹⁰, Wasserstoff sind.

5. Verfahren nach Anspruch 4, bei welchem W für Sauerstoff steht.

6. Verfahren nach Anspruch 5, bei welchem R², R³ und R⁴ Wasserstoff repräsentieren.

7. Verfahren nach Anspruch 6, bei welchem R¹ und R⁵ jeweils Methyl bedeuten.

8. Verfahren nach Anspruch 7, bei welchem 1 - [3 - Phenoxy - 2 - hydroxypropyl] - 4 - [(2,6 - dimethyl - phenyl)aminocarbonylmethyl]piperazin oder die pharmazeutisch annehmbaren Säureadditionssalze desselben hergestellt werden.

9. Verfahren nach Anspruch 7, bei welchem 1 - [3 - (2 - Methoxyphenoxy) - 2 - hydroxypropyl] - 4 - [(2,6 - dimethyl - phenyl)aminocarbonylmethyl]piperazin oder die pharmazeutisch annehmbaren Säureadditionssalze desselben hergestellt werden.

10. Verfahren nach Anspruch 9, bei welchem das R-Isomere der Verbindung oder die pharmazeutisch annehmbaren Säureadditionssalze derselben hergestellt werden.

11. Verfahren nach Anspruch 9, bei welchem S-Isomere der Verbindung oder die pharmazeutisch annehmbaren Säureadditionssalze derselben hergestellt werden.

12. Verwendung einer gemäß einem der Ansprüche 1 bis 11 hergestellten Verbindung für die Herstellung eines Medikaments.


13. Verwendung nach Anspruch 12, bei welcher das Medikament zur Verwendung bei der Behandlung von kardiovaskulären Krankheiten bestimmt ist.

Revendications pour les Etats contractants: BE CH DE FR GB IT LI LU NL SE

1. Composé de formule:

5

10




(I)


15 et ses esters et sels d'addition d'acides pharmaceutiquement acceptables, formule dans laquelle:

R¹ et R⁵ représentent chacun un groupe alkyle en C₁ à C₄;R², R³ et R⁴, identiques ou différents, représentent chacun l'hydrogène, un groupe alkyle en C₁ à C₄, alkoxy en C₁ à C₄, cyano, trifluorométhyle, halogéno, alkylthio en C₁ à C₄, alkylsulfinyle en C₁ à C₄ ou alkylsulfonyle en C₁ à C₄, un groupe alkylamido

20

25 où R¹⁶ représente indépendamment l'hydrogène ou un groupe alkyle en C₁ à C₄ et R¹⁷ est un groupe alkyle en C₁ à C₄, excepté que lorsque R¹ est un groupe méthyle, R⁴ n'est pas un groupe méthyle; ou bienR² et R³ forment ensemble un groupe —OCH₂O—;R⁶, R⁷, R⁸, R⁹ et R¹⁰, identiques ou différents, représentent l'hydrogène, un groupe acyle

30

35 où R¹⁵ est un radical alkyle en C₁ à C₄, aminocarbonylméthyle, phényle, cyano, alkyle en C₁ à C₄, alkoxy en C₁ à C₄, trifluorométhyle, halogéno, alkylthio en C₁ à C₄, alkylsulfinyle en C₁ à C₄ ou alkylsulfonyle en C₁ à C₄, di(alkyle en C₁ à C₄)amino; ou bienR⁶ et R⁷ forment ensemble un groupe —CH=CH—CH=CH—; ou bienR⁷ et R⁸ forment ensemble un groupe —OCH₂O—;R¹¹ et R¹² représentent chacun indépendamment l'hydrogène ou un groupe alkyle en C₁ à C₄; et

40

W est l'oxygène ou le soufre.

2. Composé suivant la revendication 1, dans lequel deux substituants choisis entre R², R³ et R⁴ sont de l'hydrogène et deux substituants choisis entre R⁶, R⁷, R⁸, R⁹ et R¹⁰ sont de l'hydrogène.

3. Composé suivant la revendication 2, dans lequel W est l'oxygène.

4. Composé suivant la revendication 3, dans lequel R², R³ et R⁴ sont de l'hydrogène.

45

5. Composé suivant la revendication 4, dans lequel R¹ et R⁵ sont chacun un groupe méthyle.

6. Composé suivant la revendication 5, qui est la 1 - [3 - phénoxy - 2 - hydroxypropyl] - 4 - [(2,6 - diméthylphényl)aminocarbonylméthyl]pipérazine et ses sels d'addition d'acides pharmaceutiquement acceptables.

50

7. Composé suivant la revendication 5, qui est la 1 - [3 - (2 - méthoxyphénoxy) - 2 - hydroxypropyl] - 4 - [(2,6 - diméthylphényl)aminocarbonylméthyl]pipérazine et ses sels d'addition d'acides pharmaceutiquement acceptables.

8. L'isomère R du composé suivant la revendication 7 et ses sels d'addition d'acides pharmaceutiquement acceptables.

55

9. L'isomère S du composé suivant la revendication 7 et ses sels d'addition d'acides pharmaceutiquement acceptables.

10. Composition pharmaceutique, qui comprend une quantité thérapeutiquement efficace d'un composé suivant l'une quelconque des revendications 1 à 9 en mélange avec un excipient pharmaceutiquement acceptable.

60


11. Composé suivant l'une quelconque des revendications 1 à 9, destiné à être utilisé dans le traitement de troubles cardiovasculaires.

12. Procédé de préparation d'un composé de formule (I) suivant la revendication 1 et de ses esters et sels d'addition d'acides pharmaceutiquement acceptables, procédé qui consiste à faire réagir une pipérazine portant l'un des bras en chaîne latérale du composé de formule (I) avec une source de l'autre bras en chaîne latérale du composé de formule (I); ou à transformer un sel d'un composé de formule (I) en la base libre correspondante; ou à transformer une base libre de formule (I) en un sel d'addition d'acides


65

pharmaceutiquement acceptable; ou à transformer un sel d'un composé de formule (I) en un autre sel pharmaceutiquement acceptable d'un composé de formule (I); ou à transformer un composé de formule (I) ou un sel de ce composé en un ester pharmaceutiquement acceptable; ou à séparer un composé de formule (I) ou un sel ou ester de ce composé en un stéréo-isomère.

13. Procédé suivant la revendication 12, dans lequel un composé de formule (E):



dans laquelle Ar^1 est un groupe aryle qui peut facultativement être substitué par R^6 à R^{10} comme défini dans la revendication 1, est mis en réaction avec un composé de formule (F):




dans laquelle Ar^2 représente un groupe phényle facultativement substitué et X est un groupe partant.

14. Procédé suivant la revendication 12, dans lequel un composé de formule (A):




est mis en réaction avec un composé de formule (G):



dans laquelle Ar^1 et Ar^2 sont tels que définis dans la revendication 13.

Revendications pour l'Etat contractant: AT


1. Procédé de préparation d'un composé de formule:



et de ses esters et sels d'addition d'acides pharmaceutiquement acceptables, formule dans laquelle:

R^1 et R^5 représentent chacun un groupe alkyle en C_1 à C_4 ;

R^2 , R^3 et R^4 , identiques ou différents, représentent chacun l'hydrogène, un groupe alkyle en C_1 à C_4 , alkoxy en C_1 à C_4 , cyano, trifluorométhyle, halogéno, alkylthio en C_1 à C_4 , alkylsulfinyle en C_1 à C_4 ou alkylsulfonyl en C_1 à C_4 , un groupe alkylamido



où R^{16} représente indépendamment l'hydrogène ou un groupe alkyle en C_1 à C_4 et R^{17} est un groupe alkyle en C_1 à C_4 , excepté que lorsque R^1 est un groupe méthyle, R^4 n'est pas un groupe méthyle; ou bien

R² et R³ forment ensemble un groupe —OCH₂O—;
R⁶, R⁷, R⁸, R⁹ et R¹⁰, identiques ou différents, représentent l'hydrogène, un groupe acyle



où R¹⁵ est un radical alkyle en C₁ à C₄, aminocarbonylméthyle, phényle, cyano, alkyle en C₁ à C₄, alkoxy en C₁ à C₄, trifluorométhyle, halogéno, alkylthio en C₁ à C₄, alkylsulfinyle en C₁ à C₄ ou alkylsulfonyle en C₁ à C₄,
10 di(alkyle en C₁ à C₄)amino; ou bien

R⁶ et R⁷ forment ensemble un groupe —CH=CH—CH=CH—; ou bien


R⁷ et R⁸ forment ensemble un groupe —OCH₂O—;

R¹¹ et R¹² représentent chacun indépendamment l'hydrogène ou un groupe alkyle en C₁ à C₄; et


W est l'oxygène ou le soufre;

15 procédé qui consiste à faire réagir une pipérazine portant l'un des bras en chaîne latérale du composé de formule (I) avec une source de l'autre bras en chaîne latérale du composé de formule (I); ou à transformer un sel d'un composé de formule (I) en la base libre correspondante; ou à transformer une base libre de formule (I) en un sel d'addition d'acides pharmaceutiquement acceptable, ou à transformer un sel d'un composé de formule (I) en un autre sel pharmaceutiquement acceptable d'un composé de formule (I); ou à
20 transformer un composé de formule (I) ou un sel de ce composé en un ester pharmaceutiquement acceptable; ou à séparer un composé de formule (I) ou un sel ou ester de ce composé en un stéréoisomère.

2. Procédé suivant la revendication 1, dans lequel un composé de formule (E):




30 dans laquelle Ar¹ est un groupe aryle qui peut facultativement être substitué par R⁶ à R¹⁰ tel que défini dans la revendication 1, est mis en réaction avec un composé de formule (F):




40 dans laquelle Ar² représente un groupe phényle facultativement substitué et X est un groupe partant.

3. Procédé suivant la revendication 1, dans lequel un composé de formule (A):



est mis en réaction avec un composé de formule (G):



55 dans laquelle Ar¹ et Ar² sont tels que définis dans la revendication 2.

4. Procédé suivant la revendication 1, 2 ou 3, dans lequel deux substituants choisis entre R², R³ et R⁴ sont de l'hydrogène et deux substituants choisis entre R⁶, R⁷, R⁸, R⁹ et R¹⁰ sont de l'hydrogène.

5. Procédé suivant la revendication 4, dans lequel W est l'oxygène.

60 6. Procédé suivant la revendication 5, dans lequel R², R³ et R⁴ sont de l'hydrogène.

7. Procédé suivant la revendication 6, dans lequel R¹ et R⁵ sont chacun un groupe méthyle.

8. Procédé suivant la revendication 7, dans lequel on prépare la 1 - [3 - phénoxy - 2 - hydroxypropyl] - 4 - [(2,6 - diméthylphényl)aminocarbonylméthyl]pipérazine ou ses sels d'addition d'acides pharmaceutiquement acceptables.

65 9. Procédé suivant la revendication 7, dans lequel on prépare la 1 - [3 - (2 - méthoxyphénoxy) - 2 -

hydroxypropyl] - 4 - [(2,6 - diméthylphényl)aminocarbonylméthyl]pipérazine ou ses sels d'addition d'acides pharmaceutiquement acceptables.

10. Procédé suivant la revendication 9, dans lequel on prépare l'isomère R du composé ou ses sels d'addition d'acides pharmaceutiquement acceptables.

5 11. Procédé suivant la revendication 9, dans lequel on prépare l'isomère S du composé ou ses sels d'addition d'acides pharmaceutiquement acceptables.

12. Utilisation d'un composé préparé conformément à l'une quelconque des revendications 1 à 11 pour la préparation d'un médicament.

10 13. Utilisation suivant la revendication 12, dans laquelle le médicament est destiné au traitement de troubles cardiovasculaires.

15

20

25

30

35

40

45

50

55

60

65